

CURRICULUM VITAE

Personal Information

Name: John Bernard Buse, MD, PhD

Academic Office: University of North Carolina School of Medicine
Division of Endocrinology
CB# 7172, 8027 Burnett Womack Bldg, 160 Dental Circle
Chapel Hill, NC 27599-7172
919-966-0134 (Jill Cunnup)
919-966-9978 (direct)
919-966-6025 (fax)
jbuse@med.unc.edu (e-mail)

Clinic: UNC Diabetes and Endocrinology Clinic
300 Meadowmont Village Circle
Suite 202
Chapel Hill, NC 27517-7518
984-974-2950 (phone)
984-974-2924 (fax)

Clinical Trials: UNC Diabetes Care Center
300 Meadowmont Village Circle
Suite 201
Chapel Hill, NC 27517-7518

Education

2011-2021 Recertification in Endocrinology, Diabetes and Metabolism
2001-2011 Recertification in Endocrinology, Diabetes and Metabolism
1998-2003 National Certification Board for Diabetes Educators
1994- Physician and Surgeon, State of North Carolina (#94-00739)
1991-2001 Sub-specialty Certificate in Endocrinology, Diabetes and Metabolism
1989- American Board of Internal Medicine, Certificate #129712
1988-1991 Fellow, Clinical Investigator Pathway, Section of Endocrinology, Department
of Medicine, University of Chicago
1987-1988 Resident, Internal Medicine, University of Chicago
1986-1987 Intern, Internal Medicine, University of Chicago, Chicago, IL
1986-1996 Physician and Surgeon, State of Illinois (#036-077120)
1986- Drug Enforcement Agency Registration (#BB1430432)
1982-1985 Pre-Doctoral Fellow, Joslin Diabetes Center, Boston, MA
1979-1986 M.D., Duke University, Durham, NC
Ph.D., Physiology/Immunology, Duke University, Durham, NC
1976-1979 A.B., cum laude, Dartmouth College, Hanover, NH, Biochemistry

Professional Experience – Employment History

- 2012 – Present Verne S. Caviness Distinguished Professor, University of North Carolina School of Medicine, Chapel Hill, NC
- 2006 – Present Professor, Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
- Aug 1994 - 2006 Associate Professor with tenure, Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
- July 1992 - July 1994 Assistant Professor, Section of Endocrinology, Department of Medicine, University of Chicago, Chicago, IL
- Jan 1990 - Dec 1990 Chief Resident and Instructor, Department of Medicine, University of Chicago, Chicago, IL

Honors

- 2019 American Diabetes Association's Outstanding Achievement in Clinical Diabetes Research Award
- 2019 University of Washington, John Leonard Lecturer
- 2019 *Castle Connolly TopDoctor 2019*
- 2019 *Best Doctors in America 2019*
- 2018 Expertscape #6 worldwide for "type 2 diabetes"
- 2018 *Castle Connolly TopDoctor*
- 2018 *Best Doctors in America 2018*
- 2017 Thomson Reuters "Highly Cited Researchers" in "Clinical Medicine"
- 2017 University of Utah, Levine Lecturer
- 2017 *Castle Connolly TopDoctor*
- 2017 *Best Doctors in America 2017*
- 2017 University of Chicago Kovler Diabetes Center's Donald F. Steiner Award
- 2016 *Castle Connolly TopDoctor*
- 2016 *Best Doctors in America 2016*
- 2016 Expertscape, #7 worldwide for "diabetes mellitus", #9 worldwide for "type 2 diabetes"
- 2015 Thomson Reuters "Highly Cited Researchers" in "Clinical Medicine"
- 2015 *Castle Connolly TopDoctor*
- 2015 *Best Doctors in America 2015*
- 2014 *Castle Connolly TopDoctor*
- 2014 *Best Doctors in America 2014*
- 2014 Member, American Clinical and Climatological Association
- 2014 Expertscape, #6 worldwide for "diabetes mellitus"
- 2014 Thomson Reuters "Highly Cited Researchers" in "Clinical Medicine"
- 2013 Provisional Membership, American Clinical and Climatological Association
- 2013 *Castle Connolly TopDoctor*
- 2013 *Best Doctors in America 2013*
- 2012 *Castle Connolly TopDoctor*
- 2012 *Best Doctors in America 2012*
- 2011 *Best Doctors in America 2011*
- 2011 *Castle Connolly TopDoctor*
- 2010 Castle Connolly National Physician of the Year Award for Clinical Excellence
- 2010 WCHL Hometown Hero, Chapel Hill, NC
- 2010 *Best Doctors in America 2010*

- 2009 Health Care Hero, *Triangle Business Journal*
- 2009 *Best Doctors in America 2009*
- 2008 Banting Medal, American Diabetes Association
- 2008 *Best Doctors in America 2008*
- 2007 WCHL Hometown Hero, Chapel Hill, NC
- 2007 *Best Doctors in America 2007*
- 2007 *Business North Carolina*, "Top Doctors – Endocrinology/Metabolism"
- 2006 *Best Doctors in America 2006-2007*
- 2006 *Business North Carolina*, "Top Doctors – Endocrinology/Metabolism"
- 2005 *Best Doctors in America 2005-2006*
- 2004 *Best Doctors in America 2004-2005*
- 2003 *Best Doctors in America 2003-2004*
- 2003 *Business North Carolina*, "Top Doctors – Endocrinology"
- 2002 *Business North Carolina*, One of "the top practitioners" in North Carolina
- 2002 Robert J Glaser Clinical Star, Washington University, St. Louis, MO
- 2002 *Best Doctors in America 2002-2003*
- 2001 *Best Doctors in America 2001-2002*
- 2000 Fellowship, American College of Endocrinology
- 1998 Mary Jane Kugel Award, Juvenile Diabetes Foundation International
- 1997 HOPE Health Corps Award "In recognition of your contribution in the area of medical education"
- 1997 American Diabetes Association Recognition "For outstanding leadership in the midst of change . . ."
- 1996 *American Health*, "Best Doctors in America"
- 1994 University of Chicago, Internal Medicine Resident's Teaching Recognition
- 1994 University of Chicago Pritzker School of Medicine, Medical Student Teaching Award - Class of 1994 Composite Picture
- 1993 University of Chicago, Internal Medicine Resident's Teaching Recognition
- 1992 Young Investigator Award, American Diabetes Assoc., Northern Illinois Affiliate
- 1991 Syntex/Medicine Clinical Excellence Award
- 1989 Young Investigator Award, American Diabetes Assoc., Northern Illinois Affiliate
- 1984 Novo Award, Immunology of Diabetes '84 International Symposium, Rome, Italy

Bibliography and products of scholarship

Books and Chapters:

1. Vora J and Buse J (eds). Evidence-Based Management of Diabetes. TFM Publishing Limited, Shrewsbury, UK, 2012. ISBN: 978-1-903378-78-6.
2. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 12th ed (S Melmed, KS Polonsky, PR Larsen, HM Kronenberg, eds). Saunders Elsevier Science, Philadelphia, PA. pp. 1371-1435, 2012
3. Eisenbarth GS and Buse JB. Type 1 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 12th ed (S Melmed, KS Polonsky, PR Larsen, HM Kronenberg, eds). Saunders Elsevier Science, Philadelphia, PA. pp. 1436-1461, 2012
4. Dungan KM and Buse JB. Management of type 2 diabetes mellitus. In: *Endocrinology*, 6th edition (J. Larry Jameson and Leslie J DeGroot, eds.). Saunders Elsevier, Philadelphia, PA. pp. 897-915, 2011
5. American Diabetes Association (J Buse, contributing editor). *Medical Management of Type 2 Diabetes*, 6th Edition (Charles F. Burant, Ed.) American Diabetes Association, 2009.
6. Buse JB. Diabetes standards of care. In: *The Uncomplicated Guide to Diabetes Complications*, 3rd edition. (ME Levin and MA Pfeifer, eds). American Diabetes Association, Alexandria, VA. pp. 16-25, 2009.
7. Kendall DM and Buse JB. Diabetes and cardiovascular disease – the impact of glycemic control. In: *Educational Review Manual in Endocrinology, Diabetes and Metabolism, Focus: Diabetes*, 3rd ed (DM Kendall and RM Bergenstal, eds). Castle Connolly Graduate Medical Publishing, New York, NY. Pp. 229-242, 2009.
8. Solum AM, Buse JB, O’Connell T. Pre-diabetes and the prevention of diabetes. In: *Educational Review Manual in Endocrinology, Diabetes and Metabolism, Focus: Diabetes*, 3rd ed (DM Kendall and RM Bergenstal, eds). Castle Connolly Graduate Medical Publishing, New York, NY. Pp. 289-298, 2009.
9. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 11th ed (HM Kronenberg, S Melmed, KS Polonsky, PR Larsen, eds). Elsevier Science, Philadelphia, PA. pp. 1329-89, 2008.
10. Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 11th ed (HM Kronenberg, S Melmed, KS Polonsky, PR Larsen, eds). Elsevier Science, Philadelphia, PA. pp. 1391-1416, 2008.
11. Buse JB. Scope of the problem: The diabetes-metabolic epidemic. In: *Clinical Diabetes: Translating Research into Practice*. (editor, Vivian Fonseca). Saunders, Philadelphia, PA. pp. 1-5, 2006.
12. Buse JB. Management of type 2 diabetes mellitus. In: *Endocrinology*, 5th edition (Leslie DeGroot and J. Larry Jameson, eds.). Elsevier, Philadelphia, PA. pp 1231-48, 2005.
13. Buse JB. Diabetes mellitus in adults. In: *Conn’s Current Therapy, 2005* (Robert E Rakel and Edward T Bope, editors). Saunders, Philadelphia, PA. pp. 661-670, 2005.
14. American Diabetes Association (J Buse, contributing editor). *Medical Management of Type 2 Diabetes*, 5th Edition (Charles F. Burant, Ed.) American Diabetes Association, 2004. 141 pages.
15. Buse JB. Rationale for standards of care. In: *The Cadre Handbook of Diabetes Management* (WT Cefalu, JE Gerich, D LeRoith, eds). Medical Information Press, New York, NY, 2004. pp. 29-51.
16. Buse JB and Polonsky KS. Ketoacidosis, HONKC and hypoglycemia. In: *Principles of Critical Care Medicine*, 3rd Edition (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill, New York, NY. 1209-17, 2005.

17. Buse JB. Diabetes mellitus and its complications. In: *Netter's Internal Medicine*, (MS Runge and MA Greganti, eds). Icon Learning Systems LLC, Teterboro, NJ. pp. 184-194, 2003.
18. Buse JB, Polonsky KS and Burant CF. Type 2 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 10th ed (PR Larsen, HM Kronenberg, S Melmed, KS Polonsky, eds). Elsevier Science, Philadelphia, PA. pp. 1427-1483, 2003.
19. Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus. In: *Williams Textbook of Endocrinology*, 10th ed (PR Larsen, HM Kronenberg, S Melmed, KS Polonsky, eds). Elsevier Science. pp. 1485-1508, 2003.
20. Buse JB. Insulin Resistance Syndrome. In: Blackwell Science, Oxford, UK. pp. 7-10, 2000.
21. Buse JB. The Patient with Diabetes. In: *Management of Office Emergencies* (C.W. Barton, ed). McGraw Hill, New York. pp. 73-95, 1999.
22. Nathan DM and Buse JB. Monitoring Diabetes. In: *Therapy for Diabetes Mellitus and Related Disorders*, 3rd ed (H Lebovitz, ed). American Diabetes Association, Alexandria, VA. Pp 109-117, 1998.
23. Buse JB, contributing editor. *Medical Management of Type 2 Diabetes*, 4th ed (B Zimmerman, ed). American Diabetes Association, Alexandria, VA. 1998. 141 pages.
24. Buse JB and Polonsky KS. Diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, and hypoglycemia. In: *Principles of Critical Care Medicine*, 2nd Edition. (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill, New York. pp. 1183-1193, 1998.
25. Doerr ME and Buse JB. Management of Complications of Diabetes. In: *Manual of Clinical Problems in Adult Ambulatory Care*, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds). Lippincott-Raven Publishers, Philadelphia. pp. 371-5, 1997.
26. Doerr ME and Buse JB. Management of Type II Diabetes. In: *Manual of Clinical Problems in Adult Ambulatory Care*, 3rd ed (L Dornbrand, AJ Hoole, RH Fletcher, eds). Lippincott-Raven Publishers, Philadelphia. pp. 364-71, 1997.
27. Buse JB and Doerr ME. Diabetic Ketoacidosis. In: *Conn's Current Therapy 1997* (RE Rakel, ed). W.B. Saunders Co., Philadelphia, PA. pp. 553-7, 1997.
28. Buse J and Doerr ME. The Pancreas. In: *Handbook of Endocrinology*, 3rd ed (GH Gass and HM Kaplan, eds). CRC Press, Boca Raton. pp 297-314, 1996.
29. Buse JB and Polonsky KS. Ketoacidosis, HONKC and hypoglycemia. In: *Principles of Critical Care Medicine* (JB Hall, GA Schmidt, LDH Woods, eds). McGraw Hill, New York, NY. pp 1966-76, 1992.
30. Bell GI, Buse JB, Fukumoto H, Kayano T, Seino S. Glucose transporters - molecular structure and function. In: *Genes and Gene Products in the Development of Diabetes Mellitus - Basic and Clinical Aspects* (J Nerup T Mandrup-Poulsen & B Hokfelt eds). Excerpta Medica, Amsterdam. pp. 287-97, 1990.
31. Eisenbarth GS, Jackson R, Srikanta S, Powers A, Buse J, Mori H. Utilization of monoclonal antibody techniques to study Type 1 (insulin dependent) diabetes mellitus. In: *Immunology in Diabetes* (D Andreani U DiMario KG Federlin LG Heding eds). Kimpton Medical Publications, London. pp 143-57, 1984.
32. Margolius HS and Buse JB. The renal kallikrein-kinin system. In: *Hormonal Function and the Kidney* (BM Brenner and JH Stein eds). Churchill Livingstone, New York. pp 115-45, 1979.

Refereed Papers/Articles – Original Research:

1. Wang J, Yu J, Zhang Y, Kahkoska AR, Wang Z, Fang J, Whitelegge JP, Li S, Buse JB, Gu Z. Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. *Proc Natl Acad Sci U S A*. 2019 May 16. pii: 201901967. doi: 10.1073/pnas.1901967116. [Epub ahead of print] PubMed PMID: 31097579.
2. Garry EM, Buse JB, Gokhale M, Lund JL, Nielson ME, Pate V, Stürmer T. Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes. *Diabetes Obes Metab*. 2019 May 14. doi: 10.1111/dom.13774. [Epub ahead of print] PubMed PMID: 31087620.
3. Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group. Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). *Diabetes Care*. 2019 Apr 22. pii: dc182028. doi: 10.2337/dc18-2028. [Epub ahead of print] PubMed PMID: 31010875.
4. Kahkoska AR, Adair LA, Aiello AE, Burger KS, Buse JB, Crandell J, Maahs DM, Nguyen CT, Kosorok MR, Mayer-Davis EJ. Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c. *Pediatr Diabetes*. 2019 Apr 10. doi: 10.1111/pedi.12856. [Epub ahead of print] PubMed PMID: 30972889.
5. Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, Pratley RE, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. *Diabetes Obes Metab*. 2019 Mar 9. doi: 10.1111/dom.13698. [Epub ahead of print] PubMed PMID: 30851070.
6. Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). *Diabetes Obes Metab*. 2019 Mar 8. doi: 10.1111/dom.13699. [Epub ahead of print] PubMed PMID: 30850995.
7. Danne T, Cariou B, Buse JB, Garg SK, Rosenstock J, Banks P, Kushner JA, McGuire DK, Peters AL, Sawhney S, Strumph P. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. *Diabetes Care*. 2019 May;42(5):919-930. doi: 10.2337/dc18-2149. Epub 2019 Mar 4. PubMed PMID: 30833371.
8. Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, Pratley RE, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB; DEVOTE Study Group. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin - A DEVOTE subanalysis (DEVOTE 10). *Diabetes Obes Metab*. 2019 Feb 22. doi: 10.1111/dom.13677. [Epub ahead of print] PubMed PMID: 30793465.
9. Marceau West R, Lu W, Rotroff DM, Kuenemann MA, Chang SM, Wu MC, Wagner MJ, Buse JB, Motsinger-Reif AA, Fourches D, Tzeng JY. Identifying individual risk rare variants using protein structure guided local tests (POINT). *PLoS Comput Biol*. 2019 Feb

- 19;15(2):e1006722. doi: 10.1371/journal.pcbi.1006722. [Epub ahead of print] PubMed PMID: 30779729.
10. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Furlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors. *Diabetes Care*. 2019 Feb 6. pii: dc182316. doi: 10.2337/dc18-2316. [Epub ahead of print] PubMed PMID: 30728224.
 11. Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, Stürmer T. Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Lower-Extremity Amputation: Evolving Questions, Evolving Answers. *Diabetes Obes Metab*. 2019 Jan 29. doi: 10.1111/dom.13647. [Epub ahead of print] PubMed PMID: 30697897.
 12. Wiese AD, Roumie CL, Buse JB, Guzman H, Bradford R, Zalimeni E, Knoepp P, Morris HL, Donahoo WT, Fanous N, Epstein BF, Katalenich BL, Ayala SG, Cook MM, Worley KJ, Bachmann KN, Grijalva CG, Rothman RL, Chakkalakal RJ. Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network. *Pharmacoepidemiol Drug Saf*. 2019 Jan 24. doi: 10.1002/pds.4718. [Epub ahead of print] PubMed PMID: 30680840.
 13. Alvarez PM, Young LA, Mitchell M, Blakeney TG, Buse JB, Vu MB, Weaver MA, Rees J, Grimm K, Donahue KE. Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. *Diabetes Spectr*. 2018;31:344-347. PMID: 30510390; PMCID: PMC6243228.
 14. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2018;41:2669-2701. PMID:30291106; PMC6245208.
 15. Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. *Diabetes Care*. 2019;42:258-264. PubMed PMID:30530850.
 16. Wang T, Lu W, Tang H, Buse JB, Stürmer T, Gower EW. Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. *Diabetes Care*. 2019;42:e21-e23. doi: 10.2337/dc18-1893. PMID: 30530488.
 17. Vella A, Freeman JLR, Dunn I, Keller K, Buse JB, Valcarce C. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. *Sci Transl Med*. 2019;11. pii: eaau3441. doi:10.1126/scitranslmed.aau3441. PMID: 30651321.
 18. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. *Circulation*. 2018;138:2884-2894. PMID:30566004.

19. Zhang Y, Yu J, Kahkoska AR, Wang J, Buse JB, Gu Z. Advances in transdermal insulin delivery. *Adv Drug Deliv Rev.* 2018. pii: S0169-409X(18)30309-0. doi: 10.1016/j.addr.2018.12.006. PMID:30528729.
20. Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB; and the LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. *Ann Intern Med.* 2018; doi:10.7326/M18-1569. PMID: 30508430.
21. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2018; 41:2669-2701. PMID: 30291106; PMC6245208.
22. Buse JB, Carlson AL, Komatsu M, Mosenzon O, Rose L, Liang B, Buchholtz K, Horio H, Kadowaki T. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. *Diabetes Obes Metab.* 2018;20:2885-2893. PMID: 30259644; PMC6231963.
23. Zinman B, Nauck MA, Bosch-Traberg H, Frimer-Larsen H, Ørsted DD, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and Glycaemic Outcomes in the LEADER Trial. *Diabetes Ther.* 2018;9(6):2383-2392. PMID:30392095; PMC6250637.
24. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia.* 2018;61:2461-2498. PMID: 30288571.
25. Crowley MJ, Gokhale M, Pate V, Stürmer T, Buse JB. Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. *Diabetes Obes Metab.* 2018. doi:10.1111/dom.13589. PMID: 30456843.
26. Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE. Long-Term Effects of intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. *Clin J Am Soc Nephrol.* 2018;13:1693-1702. PMID: 30361335; PMC6237052.
27. Morieri ML, Gao H, Pigeyre M, Shah HS, Sjaarda J, Mendonca C, Hastings T, Buranasupkajorn P, Motsinger-Reif AA, Rotroff DM, Sigal RJ, Marcovina SM, Kraft P, Buse JB, Wagner MJ, Gerstein HC, Mychaleckyj JC, Parè G, Doria A. Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. *Diabetes Care.* 2018;41:2404-2413. PMID: 30262460; PMC6196830.
28. Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. *Diabetes Obes Metab.* 2018;20:2532-2540. PMID: 29888547; PMC6175614.
29. Alvarez PM, Young LA, Mitchell M, Blakeney TG, Buse JB, Vu MB, Weaver MA, Rees J, Grimm K, Donahue KE. Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes. *Diabetes Spectr.* 2018;31:344-347. PMID: 30510390; PMC6243228.

30. Verma S, Leiter LA, Mazer CD, Bain SC, Buse J, Marso S, Nauck M, Zinman B, Bosch-Traberg H, Rasmussen S, Michelsen MM, Bhatt DL. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. *Circulation*. 2018;138:1605-1607. PMID: 30354517.
31. Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. *J Am Heart Assoc*. 2018;7:e009304. doi:10.1161/JAHA.118.009304. PMID: 30371301.
32. Nauck MA, Buse JB, Mann JFE, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A; LEADER Publication Committee for the LEADER Trial Investigators. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. *Diabetes Obes Metab*. 2018. doi: 10.1111/dom.13547. PMID: 30260088.
33. Garg SK, Peters AL, Buse JB, Danne T. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol. *Diabetes Technol Ther*. 2018;20:571-575. PMID: 30129772.
34. Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. *Diabetes Care*. 2018 Aug 2. pii: dc181094. doi: 10.2337/dc18-1094. [Epub ahead of print] PubMed PMID: 30072400.
35. Kahkoska AR, Brazeau NF, Lynch KA, Kirkman MS, Largay J, Young LA, Buse JB. Implementation and Evaluation of Shared Medical Appointments for Type 2 Diabetes at a Free, Student-Run Clinic in Alamance County, North Carolina. *J Med Educ Train*. 2018;2(1). pii: 032. PubMed PMID: 30035272; PubMed Central PMCID: PMC6053275.
36. Wang T, Hong JL, Gower EW, Pate V, Garg S, Buse JB, Stürmer T. Incretin-based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults. *Diabetes Care*. 2018 Jul 16. pii: dc172285. doi: 10.2337/dc17-2285. [Epub ahead of print] PubMed PMID: 30012674.
37. Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. *Diabetes Care*. 2018 Jul 12. pii: dc180087. doi: 10.2337/dc18-0087. [Epub ahead of print] PubMed PMID: 30002199.
38. Gokhale M, Buse JB, DeFilippo Mack C, Jonsson Funk M, Lund J, Simpson RJ, Stürmer T. Calendar time as an instrumental variable in assessing the risk of heart failure with antihyperglycemic drugs. *Pharmacoepidemiol Drug Saf*. 2018 Jun 26. doi: 10.1002/pds.4578. [Epub ahead of print] PubMed PMID: 29943442.
39. Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). *Diabetes Obes Metab*. 2018 Jun 25. doi: 10.1111/dom.13424. [Epub ahead of print] PubMed PMID: 29938883.

40. Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. *Diabetes Care*. 2018 Jun 24. pii: dc180343. doi: 10.2337/dc18-0343. [Epub ahead of print] PubMed PMID: 29937430.
41. Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. *Diabetes Care*. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14. PubMed PMID: 29903847.
42. Schrieks IC, Nozza A, Stähli BE, Buse JB, Henry RR, Malmberg K, Neal B, Nicholls SJ, Rydén L, Mellbin L, Svensson A, Wedel H, Weichert A, Lincoff AM, Tardif JC, Grobbee DE, Schwartz GG. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome. *Diabetes Care*. 2018 Aug;41(8):1792-1800. doi: 10.2337/dc18-0158. Epub 2018 Jun 14. PubMed PMID: 29903845.
43. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. *Diabetes Care*. 2018 Aug;41(8):1663-1671. doi: 10.2337/dc17-1825. Epub 2018 Jun 13. PubMed PMID: 29898902.
44. Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. *Diabetes Obes Metab*. 2018 Jun 11. doi: 10.1111/dom.13413. [Epub ahead of print] PubMed PMID: 29888547.
45. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. *Circulation*. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. PubMed PMID: 29760228.
46. Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group. DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK. *Diabetes Ther*. 2018 Apr 30. doi:10.1007/s13300-018-0430-4. [Epub ahead of print] PubMed PMID: 29713962.
47. Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, Wedel H, Weichert A, Lincoff AM, Grobbee DE, Tardif JC, Schwartz GG. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients with Diabetes and Acute Coronary Syndrome. *J Clin Endocrinol Metab*. 2018 Apr 6. doi: 10.1210/jc.2017-02772. [Epub ahead of print] PubMed PMID: 29659887.
48. Obeid JS, Beskow LM, Rape M, Gouripeddi R, Black RA, Cimino JJ, Embi PJ, Weng C, Marnocha R, Buse JB. A survey of practices for the use of electronic health records to support research recruitment. *J Clin Transl Sci*. 2017 Aug;1(4):246-252. doi: 10.1017/cts.2017.301. PubMed PMID: 29657859; PubMed Central PMCID: PMC5890320.
49. Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators and the

- ACCORD/ACCORDion Investigators. Genetic Variants in CPA6 and PRPF31 are Associated with Variation in Response to Metformin in Individuals with Type 2 Diabetes. *Diabetes*. 2018 Apr 12. pii: db171164. doi: 10.2337/db17-1164. [Epub ahead of print] PubMed PMID: 29650774.
50. Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial). *Am J Cardiol*. 2018 Mar 15. pii: S0002-9149(18)30266-2. doi:10.1016/j.amjcard.2018.02.030. [Epub ahead of print] PubMed PMID: 29627109.
51. Hong JL, Buse JB, Jonsson Funk M, Pate V, Stürmer T. The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. *Diabetes Care*. 2018 Apr 4. pii: dc172212. doi: 10.2337/dc17-2212. [Epub ahead of print] PubMed PMID: 29618573.
52. Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group. Longitudinal Medical Resources and Costs Among Type 2 Diabetes Patients Participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Obes Metab*. 2018 Mar 23. doi: 10.1111/dom.13292. [Epub ahead of print] PubMed PMID: 29573215.
53. Zhang Y, Wang J, Yu J, Wen D, Kahkoska AR, Lu Y, Zhang X, Buse JB, Gu Z. Bioresponsive Microneedles with a Sheath Structure for H₂O₂ and pH Cascade-Triggered Insulin Delivery. *Small*. 2018 Feb 26. doi:10.1002/sml.201704181. [Epub ahead of print] PubMed PMID: 29479811.
54. Wang J, Ye Y, Yu J, Kahkoska AR, Zhang X, Wang C, Sun W, Corder RD, Chen Z, Khan SA, Buse JB, Gu Z. Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. *ACS Nano*. 2018 Feb 19. doi: 10.1021/acsnano.7b08152. [Epub ahead of print] PubMed PMID: 29455516.
55. Rosenstock J, Buse JB, Azeem R, Prabhakar P, Kjems L, Huang H, Baron MA. Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. *Diabetes Care*. 2018 Feb;41(2):333-340. doi: 10.2337/dc17-1306. Epub 2017 Dec 14. PubMed PMID: 29242349.
56. Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. *Diabetes Care*. 2018 Jan 8. pii: dc171778. doi: 10.2337/dc17-1778. [Epub ahead of print] PubMed PMID: 29311155.
57. Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2018 Jan;41(1):14-31. doi:10.2337/dci17-0057. PubMed PMID: 29263194; PubMed Central PMCID: PMC5741160.
58. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol*. 2017 Dec 5. pii: S2213-8587(17)30412-6. doi: 10.1016/S2213-8587(17)30412-6. [Epub ahead of print] PubMed PMID: 29221659.

59. Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A. Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. *Diabetes Care*. 2018; 41:348-355. PMID: 29183908.
60. Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group. Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. *Hypertension*. 2017 Nov;70(5):907-914. doi: 10.1161/HYPERTENSIONAHA.117.09482. Epub 2017 Aug 28. PubMed PMID: 28847886; PubMed Central PMCID: PMC5638706.
61. Chen Z, Wang J, Sun W, Archibong E, Kahkoska AR, Zhang X, Lu Y, Ligler FS, Buse JB, Gu Z. Synthetic beta cells for fusion-mediated dynamic insulin secretion. *Nat Chem Biol*. 2018; 14:86-93. PMID: 29083418.
62. Crowley MJ, Williams JW Jr, Kosinski AS, D'Alessio DA, Buse JB. Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. *Diabetes Care*. 2017 Oct 19. pii: dc171528. doi: 10.2337/dc17-1528. [Epub ahead of print] PubMed PMID: 29051159.
63. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. *Diabetes Care*. 2017 Oct 6. pii: dc171091. doi: 10.2337/dc17-1091. [Epub ahead of print] PubMed PMID: 28986504.
64. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Sep 14. doi: 10.1056/NEJMoa1612917. PubMed PMID: 28910237.
65. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. *N Engl J Med*. 2017 Sep 13. doi: 10.1056/NEJMoa1708337. PubMed PMID: 28899222.
66. Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB; DEVOTE Study Group. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). *Diabetologia*. 2017 Sep 15. doi: 10.1007/s00125-017-4423-z. [Epub ahead of print] PubMed PMID: 28913575.
67. Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. *Diabetologia*. 2017 Sep 15. doi: 10.1007/s00125-017-4422-0. [Epub ahead of print] PubMed PMID: 28913543.
68. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. PubMed PMID: 28854085.
69. Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED. Hypertension

- Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. *Hypertension*. 2017 Aug 28. pii: HYPERTENSIONAHA.117.09482. doi: 10.1161/HYPERTENSIONAHA.117.09482. [Epub ahead of print] PubMed PMID: 28847886.
70. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondou N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. PubMed PMID: 28605608.
71. Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators. Genetic variants in HSD17B3, SMAD3, and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes. *Clin Pharmacol Ther*. 2017 Jul 24. doi: 10.1002/cpt.798. [Epub ahead of print] PubMed PMID: 28736931.
72. Garry EM, Buse JB, Lund JL, Pate V, Stürmer T. Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives on the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes. *Diabetes Obes Metab*. 2018; 20:129-140. PMID: 28661561.
73. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Jun 12. doi: 10.1056/NEJMoa1615692. [Epub ahead of print] PubMed PMID: 28605603.
74. Young LA, Buse JB, Weaver MA, Vu MB, Mitchell CM, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE; Monitor Trial Group. Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. *JAMA Intern Med*. 2017 Jul 1;177(7):920-929. doi:10.1001/jamainternmed.2017.1233. PubMed PMID: 28600913.
75. Craig ME, Prinz N, Boyle CT, Campbell FM, Jones TW, Hofer SE, Simmons JH, Holman N, Tham E, Fröhlich-Reiterer E, DuBose S, Thornton H, King B, Maahs DM, Holl RW, Warner JT; Australasian Diabetes Data Network (ADDN); T1D Exchange Clinic Network (T1DX); National Paediatric Diabetes Audit (NPDA) and the Royal College of Paediatrics and Child Health; Prospective Diabetes Follow-up Registry (DPV) initiative. Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents. *Diabetes Care*. 2017 Aug;40(8):1034-1040. doi: 10.2337/dc16-2508. Epub 2017 May 25. PubMed PMID: 28546222.
76. Young LA, Buse JB, Weaver MA, Vu MB, Reese A, Mitchell CM, Blakeney T, Grimm K, Rees J, Donahue KE. Three approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocol. *BMC Health Serv Res*. 2017 May 25;17(1):369. doi: 10.1186/s12913-017-2202-7. PubMed PMID: 28545493; PubMed Central PMCID: PMC5445357.
77. Marvel SW, Rotroff DM, Wagner MJ, Buse JB, Havener TM, McLeod HL, Motsinger-Reif AA; The ACCORD/ACCORDion Investigators. Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. *PeerJ*. 2017 May 2;5:e3187. doi: 10.7717/peerj.3187. eCollection 2017. PubMed PMID: 28480134; PubMed Central PMCID: PMC5417062.

78. Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. *Diabetes Care*. 2017 May 5. pii: dc162747. doi: 10.2337/dc16-2747. [Epub ahead of print] PubMed PMID: 28476871.
79. Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCCEL). *Am Heart J*. 2017 May;187:1-9. doi: 10.1016/j.ahj.2017.02.005. Epub 2017 Feb 12. PubMed PMID: 28454792.
80. Hong JL, Henderson LM, Jonsson Funk M, Lund JL, Buse JB, Pate V, Stürmer T. Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. *Pharmacoepidemiol Drug Saf*. 2017 Mar 29. doi: 10.1002/pds.4195. [Epub ahead of print] PubMed PMID: 28370798.
81. Misaghian-Xanthos N, Shariff AI, Mekala K, Fearington LR, Setji TL, Aloji JA, Buse JB. Sodium-Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions. *Diabetes Care*. 2017 Mar 28. pii: dc162591. doi: 10.2337/dc16-2591. [Epub ahead of print] PubMed PMID: 28351898.
82. Yu J, Zhang Y, Sun W, Kahkoska AR, Wang J, Buse JB, Gu Z. Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia. *Small*. 2017 Mar 20. doi: 10.1002/sml.201603028. [Epub ahead of print] PubMed PMID: 28318091.
83. Wang C, Ye Y, Sun W, Yu J, Wang J, Lawrence DS, Buse JB, Gu Z. Red Blood Cells for Glucose-Responsive Insulin Delivery. *Adv Mater*. 2017 May;29(18). doi: 10.1002/adma.201606617. Epub 2017 Mar 7. PubMed PMID: 28267235.
84. Gokhale M, Buse JB, Jonsson Funk M, Lund J, Pate V, Simpson RJ, Stürmer T. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase 4 inhibitors versus therapeutic alternatives. *Diabetes Obes Metab*. 2017. doi: 10.1111/dom.12906. PubMed PMID: 28195389.
85. Hong JL, Funk MJ, Buse J, Henderson LM, Lund JL, Pate V, Stürmer T. Comparative effect of Initiating Metformin versus Sulfonylureas on Breast Cancer Risk in Older Women. *Epidemiology*. 2017. 28(3):446-454. PMID: 28166101.
86. Yu J, Qian C, Zhang Y, Cui Z, Zhu Y, Shen Q, Ligler FS, Buse JB, Gu Z. Hypoxia and H(2)O(2) Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery. *Nano Lett*. 2017;17(2):733-739. PMID: 28079384.
87. Hu X, Yu J, Qian C, Lu Y, Kahkoska AR, Xie Z, Jing X, Buse JB, Gu Z. H(2)O(2)-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery. *ACS Nano*. 2017;11(1):613-620. doi: 10.1021/acsnano.6b06892. PubMed PMID: 28051306.
88. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators.. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. *JAMA Cardiol*. 2016 Dec 28. doi: 10.1001/jamacardio.2016.4828. [Epub ahead of print] PubMed PMID: 28030716.
89. El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ.

- Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. *Lancet*. 2017;389(10067):369-380. doi: 10.1016/S0140-6736(16)32567-3. PubMed PMID: 28007348.
90. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2016 Nov 10;375(19):1834-1844. PubMed PMID: 27633186.
 91. Graham HT, Rotroff DM, Marvel SW, Buse JB, Havener TM, Wilson AG, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators. Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. *Front Genet*. 2016 Aug 17;7:138. PubMed PMID: 27775101; PubMed Central PMCID: PMC5013254.
 92. Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care*. 2016;39(7):1186-201. PMID: 27631469.
 93. Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group. Pancreatic Safety of Sitagliptin in the TECOS Study. *Diabetes Care*. 2016 Sep 14. pii: dc152780. [Epub ahead of print] PMID: 27630212.
 94. Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group. Sitagliptin and Risk of Fractures in Type 2 Diabetes: Results from the TECOS Trial. *Diabetes Obes Metab*. 2016; Oct 6. doi: 10.1111/dom.12786. PMID: 27607571.
 95. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabøl R, Buse JB. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. *Am Heart J*. 2016 Sep;179:175-83. PMID: 27595693.
 96. ACCORD Study Group, Gerstein HC, Beavers DP, Bertoni AG, Bigger JT, Buse JB, Craven TE, Cushman WC, Giddings SJ, Seaquist ER, Grimm RH, Fonseca V, Geller NL, Genuth S, Hramiak I, Ismail-Beigi F, Kirby R, Lopez-Jimenez CR, Probstfields J, Riddle MC, Friedewald WT. 9-year Effects of 3.7 Years of Intensive Glycemia Control on Cardiovascular Outcomes. *Diabetes Care* 2016. In Press. PMID: 26822326.
 97. ACCORDION Eye Study Group and ACCORDION Study Group, Chew EY, Lovato JF, Davis MD, Gerstein HC, Danis RP, Ismail-Beigi F, Genuth S, Greven CM, Perdue LH, Cushman WC, Elam MB, Bigger JT, Ginsberg HN, Goff DC, Ambrosius WT. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. *Diabetes Care* 2016. In Press.
 98. Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Paré G, Mannino GC, Buranasupkajorn P, Mendonca C, Hastings T, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A. Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. *Diabetes Care*. 2016; 39:1915-1924. PMID: 27527847.
 99. Ahrén B, Hirsch IB, Pieber TR, Mathieu C, Gómez-Peralta F, Hansen TK, Philotheou A, Birch S, Christiansen E, Jensen TJ, Buse JB; ADJUNCT TWO investigators. Efficacy and

- Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: the ADJUNCT TWO Randomized Trial. *Diabetes Care*. 2016; 39:1693-701. PubMed PMID: 27493132.
100. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2016; 1:126-35. PubMed PMID: 27437883.
 101. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016; 375:311-22. PubMed PMID: 27295427; PubMed Central PMCID: PMC4985288.
 102. Rutten GE, Tack CJ, Pieber TR, Comlekci A, Ørsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators. LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. *Diabetol Metab Syndr*. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016. PubMed PMID: 27274772; PubMed Central PMCID: PMC4891842.
 103. Burant CF, Buse CR, Robinson KA, Buse JB. Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. *Diabetes Care*. 2016; 39:852-6. PubMed PMID: 27222542.
 104. DeFronzo RA, Buse JB, Kim T, Burns C, Skare S, Baron A, Fineman M. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. *Diabetologia*. 2016; 59:1645-54. PubMed PMID: 27216492. [PMC4930485](#)
 105. Htoo PT, Buse JB, Gokhale M, Marquis MA, Pate V, Stürmer T. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. *Eur J Clin Pharmacol*. 2016; 72:1013-23. PMID: 27165664.
 106. Jago R, Drews KL, Otvos JD, Willi SM, Buse JB. Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study. *Int J Obes (Lond)*. 2016; 40:1157-63. PubMed PMID: 27143035.
 107. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *N Engl J Med*. 2016; 374(14):1321-31. PubMed PMID: 26886418.
 108. Irvin MR, Rotroff DM, Aslibekyan S, Zhi D, Hidalgo B, Motsinger-Reif A, Marvel S, Srinivasasainagendra V, Claas SA, Buse JB, Straka RJ, Ordovas JM, Borecki IB, Guo X, Chen IY, Rotter JI, Wagner MJ, Arnett DK. A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies. *Pharmacogenet Genomics*. 2016; 26(7):324-33. PMID: 27002377.
 109. Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC, Iqbal N, Kundu S, Maggioni AP, Marso SP, Öhman P, Pencina MJ, Poulter N, Porter LE, Ramachandran A, Zinman B, Hernandez AF. Rationale

- and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. *Am Heart J.* 2016; 174:103-10. PMID: 26995376.
110. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. *JAMA.* 2016; 315(10):990-1004. PMID: 26954408.
 111. Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB; DUAL V Investigators. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. *JAMA.* 2016; 315(9):898-907. PMID: 26934259.
 112. Ye Y, Yu J, Wang C, Nguyen NY, Walker GM, Buse JB, Gu Z. Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery. *Adv Mater.* 2016; 28(16):3115-3121. PMID: 26928976.
 113. Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, Liljenquist DR, Aleppo G, Buse JB, Kruger D, Bhargava A, Goland RS, Edelen RC, Pratley RE, Peters AL, Rodriguez H, Ahmann AJ, Lock JP, Garg SK, Rickels MR, Hirsch IB; T1D Exchange Severe Hypoglycemia in Older Adults with Type 1 Diabetes Study Groups. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. *Diabetes Care.* 2015; 39(4):603-610. PubMed PMID: 26681721.
 114. Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM; IMAGINE 5 Investigators. Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. *Diabetes Care.* 2016; 39:92-100. PubMed PMID: 26577417.
 115. Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, Buse JB, Genuth S, Joyce C, Kovacs CS, O'Connor PJ, Sigal RJ, Solomon S; ACCORD Investigators. Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. *Diabetes Care.* 2015; 38:2000-8. PMID: 26464212.
 116. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group.. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. *Diabetes Obes Metab.* 2016; 18(1):82-91. PMID:26450639.
 117. Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, Kvist K, Gough SC. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. *J Diabetes Sci Technol.* 2015 *Diabetes Care.* 2015; 38:2000-8. PubMed PMID: 26443290.
 118. Gokhale M, Buse JB, Pate V, Marquis MA, Stürmer T. More realistic power estimation for new user, active comparator studies: an empirical example. *Pharmacoepidemiol Drug Saf.* 2015 Sep 11. doi: 10.1002/pds.3872. [Epub ahead of print] PubMed PMID: 26360635.
 119. Rodbard HW, Buse JB, Woo V, Vilsbøll T, Langbakke IH, Kvist K, Gough SC. Benefits of combination of insulin degludec and liraglutide (IDegLira) are independent of baseline HbA(1c) and duration of type 2 diabetes. *Diabetes Obes Metab.* 2015 Sep 7. doi: 10.1111/dom.12574. [Epub ahead of print] PubMed PMID:26343931.

120. Buse JB. Glycemic Targets in Diabetes Care: Emerging Clarity after Accord. *Trans Am Clin Climatol Assoc.* 2015;126:62-76. PubMed PMID: 26330660; PubMed Central PMCID: PMC4530694.
121. Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation. Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. *Diabetes Care.* 2015; 39(2):198-205. PMID: 26285584.
122. Selker HP, Buse JB, Califf RM, Carter R, Cooper DM, Davis J, Ford DE, Galassetti P, Guay-Woodford L, Huggins GS, Kasper A, Kiebertz K, Kirby A, Klein AK, Kline J, O' Neill RT, Rape M, Reichgott DJ, Rojevsky S, Rosenthal GE, Rubinstein EP, Shepherd A, Stacy M, Terrin N, Wallace M, Welch L. CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes. *Clin Transl Sci.* 2015; 8(6):623-31. PMID:26184433. PMC
123. DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, Schwab KO, Holl RW, Hofer SE, Maahs DM; Type 1 Diabetes Exchange Clinic Network and Diabetes Prospective Follow-up Registry. Obesity in Youth with Type 1 Diabetes in Germany, Austria, and the United States. *J Pediatr.* 2015;167(3):627-632. PMID: 26164381.
124. Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, Ligler FS, Buse JB, Gu Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. *Proc Natl Acad Sci U S A.* 2015; 112(27):8260-5. PMID:26100900; PMC4500284.
125. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. *Diabetes Care.* 2015 Sep;38(9):1687-93. PMID: 26078479; PMC4542270.
126. Mendez MA, González-Horta C, Sánchez-Ramírez B, Ballinas-Casarrubias L, Hernández Cerón R, Viniegra Morales D, Baeza Terrazas FA, Ishida MC, Gutiérrez-Torres DS, Saunders RJ, Drobná Z, Fry RC, Buse JB, Loomis D, García-Vargas GG, Del Razo LM, Stýblo M. Chronic Exposure to Arsenic and Markers of Cardiometabolic Risk-A Cross-Sectional Study in Chihuahua, Mexico. *Environ Health Perspect.* 2015; 124(1):104-11. PMID: 26068977. PMC
127. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med.* 2015; 373(3):232-42. PMID: 26052984.
128. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. *Diabetes Care.* 2015; 38(7):1181-8. PMID: 26049551. PMC
129. Gough SC, Bode B, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. *Diabetes Obes Metab.* 2015; 17(10):965-73. PMID: 25980900. PMC
130. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. *Diabetes Care.* 2015; 38(6):1067-74. PMID: 25887355; PMC4439529.

131. Kahn SE, Buse JB. Medications for type 2 diabetes: how will we be treating patients in 50 years? *Diabetologia*. 2015; 58(8):1735-9. PMID: 25773402. PMC
132. Henry RR, Buse JB, Wu H, Durrwell LM, Mingrino R, Jaekel KE, Azzouzi BE, Andjelkovic M, Herz M. Efficacy, safety and tolerability of alogliptazar in patients with type 2 diabetes: pooled findings from three randomized Phase III trials. *Diabetes Obes Metab*. 2015; 17(6):560-5. PMID: 25728612.
133. Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic Network. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. *Pediatrics*. 2015; 135(3):424-34. PMID: 25687140; PMC4533245.
134. Espeland MA, Probstfield J, Hire D, Redmon JB, Evans GW, Coday M, Lewis CE, Johnson KC, Wilmoth S, Bahnson J, Dulin MF, Green JB, Knowler WC, Kitabchi A, Murillo AL, Osei K, Rehman SU, Cushman WC; Look AHEAD Research Group; ACCORD Study Group. Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. *Am J Hypertens*. 2015; 28(8):995-1009. PMID:25666468; PMC4506323.
135. Seshasai SR, Bennett RL, Petrie JR, Bengus M, Ekman S, Dixon M, Herz M, Buse JB, Ray KK. Cardiovascular safety of the GLP-1 receptor agonist taspoglutide in people with type 2 diabetes: An individual participant data meta-analysis of randomized controlled trials. *Diabetes Obes Metab*. 2015; 17(5):505-510. PMID: 25656522.
136. Daniels GH, Hegedüs L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbøl J, Moses AC, Buse JB, Tuttle RM; on behalf of the LEADER trial investigators. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. *Diabetes Obes Metab*. 2015; 17(5):477-86. PMID: 25656058.
137. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan;38(1):140-9. PMID:25538310 -- and -- *Diabetologia*. 2015; 58(3):429-42. PMID: 25583541.
138. Martin E, González-Horta C, Rager J, Bailey KA, Sánchez-Ramírez B, Ballinas-Casarrubias L, Ishida MC, Gutiérrez-Torres DS, Hernández Cerón R, Viniegra Morales D, Baeza Terrazas FA, Jesse Saunders R, Drobná Z, Mendez MA, Buse JB, Loomis D, Jia W, García-Vargas GG, Del Razo LM, Stýblo M, Fry R. Metabolomic Characteristics of Arsenic-Associated Diabetes in a Prospective Cohort in Chihuahua, Mexico. *Toxicol Sci*. 2015; 144(2):338-46. PMID: 25577196; PMC
139. Lim S, Stember KG, He W, Bianca PC, Yelibi C, Marquis A, Stürmer T, Buse JB, Meigs JB. Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. *PLoS One*. 2014; 9(10):e109433. doi: 10.1371/journal.pone.0109433. PMID:25329887; PMC4203726.
140. Buse JB, Peters A, Russell-Jones D, Furber S, Donsmark M, Han J, MacConell L, Maggs D, Diamant M. Is insulin the most effective injectable antihyperglycaemic therapy? *Diabetes Obes Metab*. 2014; 17(2):145-51. PMID: 25323312.
141. Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators. LEADER 3-Lipase and Amylase Activity in Subjects With Type 2 Diabetes:

- Baseline Data From Over 9000 Subjects in the LEADER Trial. *Pancreas*. 2014; 43(8):1223-31. PMID: 25275271; PMC4206347.
142. Tai W, Mo R, Di J, Subramanian V, Gu X, Buse JB, Gu Z. Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. *Biomacromolecules*. 2014; 15(10):3495-502. PMID: 25268758; PMC4195518.
 143. Phillips LS, Ratner RE, Buse JB, Kahn SE. We can change the natural history of type 2 diabetes. *Diabetes Care*. 2014; 37(10):2668-76. PMID: 25249668; PMC4170125.
 144. Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; on behalf of the NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. *Lancet Diabetes Endocrinol*. 2014; 2(11):885-93. PMID: 25190523.
 145. Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. *J Diabetes Complications*. 2014; 28(6):874-9. PMID: 25123755.
 146. Cefalu WT, Buse JB, Del Prato S, Home PD, LeRoith D, Nauck MA, Raz I, Rosenstock J, Riddle MC. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. *Diabetes Care*. 2014; 37(9):2647-59. PMID: 25147257.
 147. Kahn HS, El Ghormli L, Jago R, Foster GD, McMurray RG, Buse JB, Stadler DD, Treviño RP, Baranowski T, Healthy Study Group. Cardiometabolic Risk Assessments by Body Mass Index z-Score or Waist-to-Height Ratio in a Multiethnic Sample of Sixth-Graders. *J Obes*. 2014; 2014:421658. PMID:25132986; PMC4123559.
 148. Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Böttcher SG, Rodbard HW; and on behalf of the NN9068-3912 (DUAL-II) Trial Investigators. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). *Diabetes Care* 37(11): 2926-33, 2014. PubMed PMID: 25114296.
 149. Gokhale M, Buse JB, Gray CL, Pate V, Marquis MA, Stürmer T. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. *Diabetes Obes Metab*. 2014; 16(12):1247-56. PMID: 25109825; PMC.
 150. Currier JM, Ishida MC, González-Horta C, Sánchez-Ramírez B, Ballinas-Casarrubias L, Gutiérrez-Torres DS, Hernández Cerón R, Viniegra Morales D, Baeza Terrazas FA, Del Razo LM, García-Vargas GG, Saunders RJ, Drobná Z, Fry RC, Matoušek T, Buse JB, Mendez MA, Loomis D, Stýblo M. Associations between Arsenic Species in Exfoliated Urothelial Cells and Prevalence of Diabetes among Residents of Chihuahua, Mexico. *Environ Health Perspect*. 2014; 122(10):1088-94. PMID: 25000461; PMC
 151. Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. *Diabetes Obes Metab*. 2014; 16(10):1016-27. PubMed PMID: 24965700.
 152. Garg SK, Buse JB, Skyler JS, Vaughn DE, Muchmore DB. Subcutaneous Injection of Hyaluronidase with Recombinant Human Insulin Compared with Insulin Lispro in Type 1 Diabetes. *Diabetes Obes Metab*. 2014; 16(11):1065-9. PMID: 24840317.
 153. Whitfield-Larry F, Felton J, Buse J, Su MA. Myeloid-derived suppressor cells are increased in frequency but not maximally suppressive in peripheral blood of Type 1 Diabetes Mellitus patients. *Clin Immunol*. 2014; 153(1):156-64. PMID: 24769355.

154. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA*. 2014; 311(15):1515-25. PMID: 24682069.
155. Buse JB, Han J, Miller S, Macconell L, Pencek R, Wintle M. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. *Curr Med Res Opin*. 2014; 30(7):1209-18. PMID: 24621255.
156. Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, Lipkin EW, Venkat Narayan KM, Riddle MC Jr, Sood A, Goff DC Jr. Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. *Diabetes Care*. 2014; 37(6):1721-8. PMID: 24595629; PMC
157. Jago R, Drews KL, Otvos JD, Foster GD, Marcus MD, Buse JB, Mietus-Snyder M, Willi SM; HEALTHY Study Group. Effect of Relative Weight Group Change on Nuclear Magnetic Resonance Spectroscopy Derived Lipoprotein Particle Size and Concentrations among Adolescents. *J Pediatr*. 2014; 164(5):1091-1098.e3. PMID: 24508445; PMC3992168.
158. Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, Marcovina S, Lovato L, Lovato J, Margolis KL, Davatzikos C, Barzilay J, Ginsberg HN, Linz PE, Miller ME; Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Investigators. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med*. 2014; 174(3):324-33. PMID: 24493100; PMC.
159. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. *Am Heart J*. 2013; 166(5):823-30.e5. PMID: 24176437.
160. Bencharit S, Baxter SS, Carlson J, Byrd WC, Mayo MV, Border MB, Kohltfarber H, Urrutia E, Howard-Williams EL, Offenbacher S, Wu MC, Buse JB. Salivary proteins associated with hyperglycemia in diabetes: a proteomic analysis. *Mol Biosyst*. 2013; 9(11):2785-97. PMID: 24056972; PMC
161. Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. *Am Heart J*. 2013; 166(3):429-34. PMID: 24016490.
162. Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW, Cengiz E, Laffel LM, Miller KM, Haller MJ; T1D Exchange Clinic Network. A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. *Pediatr Diabetes*. 2014; 15(2):110-7. PMID: 23957219; PMC4164957.
163. Stürmer T, Marquis MA, Zhou H, Meigs JB, Lim S, Blonde L, Macdonald E, Wang R, Lavange LM, Pate V, Buse JB. Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. *Diabetes Care*. 2013; 36(11):3517-25. PMID: 23877991; PMC
164. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate

- (salsalate) in patients with type 2 diabetes: a randomized trial. *Ann Intern Med.* 2013; 159(1):1-12. PMID:23817699; PMC4128629.
165. Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, Bergenstal RM, Harris B, Dubose SN, Miller KM, Beck RW; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. *J Clin Endocrinol Metab.* 2013; 98(8):3411-9. PMID: 23760624.
166. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 Trial Investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. *Diabet Med.* 2013; 30(11):1293-7. PMID: 23710902; PMC
167. Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes Obes Metab.* 2013; 16(3):206-14. PMID: 23711193.
168. Raz I, Riddle MC, Rosenstock J, Buse JB, Inzucchi SE, Home PD, Del Prato S, Ferrannini E, Chan JC, Leiter LA, Leroith D, DeFronzo R, Cefalu WT. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. *Diabetes Care.* 2013; 36(6):1779-88. PMID: 23704680; PMC3661796.
169. Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, Wexler D, Lachin JM; GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). *Diabetes Care.* 2013; 36(8):2254-61. PMID: 23690531; PMC3714493.
170. Mietus-Snyder M, Drews KL, Otvos JD, Willi SM, Foster GD, Jago R, Buse JB; HEALTHY Study Group. Low-density lipoprotein cholesterol versus particle number in middle school children. *J Pediatr.* 2013; 163(2):355-62. PMID: 23415622; PMC3659184.
171. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, Gerstein HC, Ismail-Beigi F, Morgan TM, Pop-Busui R, Riddle MC; ACCORD Study Group. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. *Diabetes Care.* 2013; 36(8):2162-8. PMID: 23412077; PMC3714487.
172. Wood JR, Miller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Quinn M, Tamborlane WV, Woerner SE; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. *Diabetes Care.* 2013; 36(7):2035-7. PMID: 23340893; PMC3687259.
173. Hasstedt SJ, Highland HM, Elbein SC, Hanis CL, Das SK; American Diabetes Association GENNID Study Group. Five linkage regions each harbor multiple type 2 diabetes genes in the African American subset of the GENNID Study. *J Hum Genet.* 2013; 58(6):378-83. PMID: 23552671; PMC3692593.
174. Roep BO, Solvason N, Gottlieb PA, Abreu JR, Harrison LC, Eisenbarth GS, Yu L, Leviten M, Hagopian WA, Buse JB, von Herrath M, Quan J, King RS, Robinson WH, Utz PJ, Garren H; The BHT-3021 Investigators, Steinman L. Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes. *Sci Transl Med.* 2013; 5(191):191ra82. PubMed PMID: 23803704; PMC
175. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, Larsen J, Tamer SC, Bain SC; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients

- with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab.* 2013; 98(3):1154-62. PMID: 23393185; PMC3612802.
176. Jago R, Drews KL, McMurray RG, Baranowski T, Galassetti P, Foster GD, Moe E, Buse JB. BMI Change, Fitness Change and Cardiometabolic Risk Factors Among 8th Grade Youth. *Pediatr Exerc Sci.* 2013; 25(1):52-68. PMID: 23406707; PMC
177. Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S; HEALTHY Study Group. Diabetes screening with hemoglobin A1c versus fasting plasma glucose in a multiethnic middle-school cohort. *Diabetes Care.* 2013; 36(2):429-35. PMID: 23193207; PMC3554290.
178. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med.* 2012; 367(25):2375-84. PMID: 23121323.
179. Ali MK, Feeney P, Hire D, Simmons DL, O'Connor PJ, Ganz-Lord F, Goff D Jr, Zhang P, Andersen R, V Narayan KM, Sullivan MD. Glycaemia and correlates of patient-reported outcomes in ACCORD trial participants. *Diabet Med* 2012;29:e67-e74. PMID: 22141437.
180. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. *J Clin Endocrinol Metab.* 2012; 97(12):4383-9. PMID: 22996145.
181. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Scherthaner G. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. *Lancet.* 2013; 381(9861):117-24. PMID:23141817
182. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, Zinman B. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. *Diabetes Obes Metab.* 2013; 15(1):42-54. PMID: 22862847.
183. Lopes MH, Southerland JH, Buse JB, Malone RM, Wilder RS. Diabetes educators' knowledge, opinions and behaviors regarding periodontal disease and diabetes. *J Dent Hyg.* 2012;86(2):82-90. PMID: 22584445.
184. Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, Kimel AR, Pedley CF, Cushman WC. Intensive Blood Pressure Treatment Does Not Improve Cardiovascular Outcomes in Centrally Obese Hypertensive Individuals With Diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. *Diabetes Care* 2012; 35:1401-5. PMID: 22723577 PMCID: PMC3379577.
185. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia.* 2012; 55(6):1577-96. PMID: 22526604 – and -- *Diabetes Care.* 2012; 35(6):1364-79. PMID: 22517736; PMC3357214.

186. Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of Sensor-Augmented Pump Therapy on Glycemic Variability in Well-Controlled Type 1 Diabetes in the STAR 3 Study. *Diabetes Technol Ther.* 2012 14:644-7. PMID: 22524549; PMC4516024
187. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B; BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012; 379(9825):1489-97. PMID: 22521071.
188. Willi SM, Hirst K, Jago R, Buse J, Kaufman F, El Ghormli L, Bassin S, Elliot D, Hale DE; HEALTHY Study Group. Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial. *Pediatr Obes.* 2012; 7(3):230-9. PMID: 22461375; PMC3348358.
189. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. *Diabetes Care.* 2012; 35(5):1008-14. PMID: 22432114; PMC3329840.
190. Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. *Diabetologia.* 2012; 55(6):1641-50. PMID: 22450889; PMC3374398.
191. Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. *Diabetes Care.* 2012; 35(5):955-8. PMID: 22432107; PMC3329851.
192. Dungan KM, Buse JB, Herman WH, Arakaki RF, Jiang HH, Jacobson JG, Fahrback JL. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. *Diabetes Res Clin Pract.* 2012; 96(3):e66-9. PMID: 22421598.
193. Tandon S, Wackers FJ, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH; DIAD Investigators. Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study. *Diab Vasc Dis Res.* 2012; 9(2):124-30. PMID: 22228772.
194. Border MB, Schwartz S, Carlson J, Dibble CF, Kohltfarber H, Offenbacher S, Buse JB, Bencharit S. Exploring salivary proteomes in edentulous patients with type 2 diabetes. *Mol Biosyst.* 2012; 8(4):1304-10. PubMed PMID: 22314925.
195. HEALTHY Study Group, Mobley CC, Stadler DD, Staten MA, El Ghormli L, Gillis B, Hartstein J, Siega-Riz AM, Virus A. Effect of nutrition changes on foods selected by students in a middle school-based diabetes prevention intervention program: the HEALTHY experience. *J Sch Health.* 2012; 82(2):82-90. PMID: 22239133; PMC3261591.
196. Rubin RR, Peyrot M; STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial. *Diabetes Technol Ther.* 2012; 14(2):143-51. PMID: 22133037; PMC.
197. Langberg KA, Ma L, Sharma NK, Hanis CL, Elbein SC, Hasstedt SJ, Das SK; American Diabetes Association GENNID Study Group. Single nucleotide polymorphisms in JAZF1 and BCL11A gene are nominally associated with type 2 diabetes in African-

- American families from the GENNID study. *J Hum Genet.* 2012; 57(1):57-61. PMID: 22113416; PMC3266455.
198. Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, Pratley RE. Efficacy of Anthihyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. *Endocr Pract.* 2011; 17(6):906-13. PubMed PMID: 22193143.
199. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; ACCORD MIND investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol.* 2011; 10(11):969-77. PMID: 21958949; PMC
200. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. *Diabetes Care.* 2011; 34(11):2403-5. PMID: 21933908; PMC3198292.
201. DeBar LL, Schneider M, Drews KL, Ford EG, Stadler DD, Moe EL, White M, Hernandez AE, Solomon S, Jessup A, Venditti EM; HEALTHY study group. Student public commitment in a school-based diabetes prevention project: impact on physical health and health behavior. *BMC Public Health.* 2011; 11:711. PMID: 21933431; PMC3189889.
202. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies--review of the scientific evidence. *J Clin Endocrinol Metab.* 2011; 96(7):2027-31. PMID: 21734003.
203. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, Jensen TM, Buse JB. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. *Diab Vasc Dis Res.* 2011; 8(3):237-40. PMID: 21653676.
204. Herman WH, Buse JB, Arakaki RF, Dungan KM, Jiang HH, Jacobson JG, Fahrback JL. Concomitant Oral Antihyperglycemic Agent Use is Associated with Treatment Outcomes after Insulin Initiation. *Endocr Pract.* 2011; 17(4):563-7. PMID: 21550959.
205. Whitfield-Larry F, Young EF, Talmage G, Fudge E, Azam A, Patel S, Largay J, Byrd W, Buse J, Calikoglu AS, Shultz LD, Frelinger JA. HLA-A2-Matched Peripheral Blood Mononuclear Cells From Type 1 Diabetic Patients, but Not Nondiabetic Donors, Transfer Insulinitis to NOD-scid/ γ cnul/HLA-A2 Transgenic Mice Concurrent With the Expansion of Islet-Specific CD8⁺ T cells. *Diabetes.* 2011; 60(6):1726-33. PMID: 21521873; PMC3114397.
206. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA.* 2011; 305(16):1659-68. PMID: 21521847; PMC3110082.
207. Buse JB, Dailey G, Ahmann AA, Bergenstal RM, Green JB, Peoples T, Tanenberg RJ, Yang Q. Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience. *Diabetes Technol Ther.* 2011; 13(6):601-6. PMID: 21488717; PMC3101919.
208. Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, Holst J, Nauck M. Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody

- Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. *J Clin Endocrinol Metab.* 2011; 96(6):1695-702. PMID: 21450987.
209. Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons DL, Sperl-Hillen JA, Bigger T, Cuddihy R, O'Conner PJ, Sood A, Zhang P, Sullivan MD; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. *Diabetes Care* 2011; 34:807-12. PMID: 21346183; PMC3064032.
210. Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. *Diabet Med.* 2011; 28(6):715-23. PMID: 21388442.
211. Owens JB, Wilder RS, Southerland JH, Buse JB, Malone RM. North Carolina internists' and endocrinologists' knowledge, opinions, and behaviors regarding periodontal disease and diabetes: need and opportunity for interprofessional education. *J Dent Educ.* 2011; 75(3):329-38. PubMed PMID: 21368257.
212. ACCORD Study Group, Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH Jr, Byington RP, Rosenberg YD, Friedewald WT. Long-term effects of intensive glucose lowering on cardiovascular outcomes. *N Engl J Med.* 2011; 364(9):818-28. PMID: 21366473; PMC
213. Siega-Riz AM, El Ghormli L, Mobley C, Gillis B, Stadler D, Hartstein J, Volpe SL, Virus A, Bridgman J; HEALTHY Study Group. The effects of the HEALTHY study intervention on middle school student dietary intakes. *Int J Behav Nutr Phys Act.* 2011; 8:7. PMID: 21294869; PMC3041997.
214. Buse JB, Wolffenbuttel BH, Herman WH, Hippler S, Martin SA, Jiang HH, Shenouda SK, Fahrback JL. The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargine. *Diabetes Care.* 2011; 34(2):249-55. PMID: 21270182; PMC3024329.
215. Thethi T, Rajapurkar M, Walker P, McDuffie R, Goff DC Jr, Probstfield J, Yau CL, Shah S, Christians U, Buse J, Fonseca V. Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria--a substudy of the ACCORD Trial. *Clin Chem.* 2011; 57(2):341-4. PMID: 21159897.
216. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial. *Ann Intern Med.* 2011; 154(2):103-12. PMID: 21138825.
217. Schneider A, Alexis NE, Diaz-Sanchez D, Neas LM, Harder S, Herbst MC, Cascio WE, Buse JB, Peters A, Devlin RB. Ambient PM2.5-Exposure Up-regulates the Expression of Co-Stimulatory Receptors on Circulating Monocytes in Diabetic Individuals. *Environ Health Perspect.* 2011; 119:778-783. PMID: 21169129; PMC
218. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet.* 2010; 376(9739):419-30. PMID: 20594588; PMC

219. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet*. 2010; 376(9739):431-9. PMID: 20580422.
220. HEALTHY Study Group, Foster GD, Linder B, Baranowski T, Cooper DM, Goldberg L, Harrell JS, Kaufman F, Marcus MD, Treviño RP, Hirst K. A school-based intervention for diabetes risk reduction. *N Engl J Med*. 2010; 363(5):443-53. PMID: 20581420; PMC2924187.
221. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*. 2010; 363(3):233-44. PMID: 20587587; PMC
222. Al-Arouj M, Assaad-Khalil S, Buse J, Fahdil I, Fahmy M, Hafez S, Hassanein M, Ibrahim MA, Kendall D, Kishawi S, Al-Madani A, Nakhi AB, Tayeb K, Thomas A. Recommendations for management of diabetes during Ramadan: update 2010. *Diabetes Care*. 2010; 33(8):1895-902. PMID: 20668157; PMC2909082.
223. Hasstedt SJ, Hanis CL, Elbein SC; American Diabetes Association GENNID Study Group. Univariate and bivariate linkage analysis identifies pleiotropic loci underlying lipid levels and type 2 diabetes risk. *Ann Hum Genet*. 2010; 74(4):308-15. PMID: 20597901; PMC
224. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *N Engl J Med*. 2010; 363(4):311-20. PMID: 20587585.
225. Schneider A, Neas LM, Graff DW, Herbst MC, Cascio WE, Schmitt MT, Buse JB, Peters A, Devlin RB. Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. *Part Fibre Toxicol*. 2010; 7:14. PMID: 20525188; PMC
226. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. *Diabetes Care*. 2010; 33(5):983-90. PMID: 20427682; PMC
227. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E, Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. *Lancet*. 2010; 375(9723):1365-74. PMID: 20356621.
228. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. *Diabetes Care*. 2010; 33(6):1300-3. PMID: 20332351
229. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010; 362(17):1563-74. PMID: 20228404; PMC

230. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010; 362(17):1575-85. PMID: 20228401; PMC
231. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE; DURATION-1 Study Group. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. *Diabetes Care.* 2010; 33(6):1255-61. PMID: 20215461.
232. Ambrosius WT, Danis RP, Goff DC Jr, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY; ACCORD Study Group. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. *Arch Ophthalmol.* 2010; 128(3):312-8. PMID: 20212201.
233. NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med.* 2010; 362(16):1477-90. PMID: 20228403.
234. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. Effect of nateglinide on the incidence of diabetes and cardiovascular events. *N Engl J Med.* 2010; 362(16):1463-76. PMID: 20228402.
235. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. *Diabetes Care.* 2010; 33(2):428-33. PMID: 20103558; PMC
236. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. *BMJ.* 2010; 340:b4909. PMID: 20061358; PMC2803744.
237. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *BMJ.* 2010 Jan 8;340:b5444. doi: 10.1136/bmj.b5444. PubMed PMID: 20061360; PubMed Central PMCID: PMC2803743.

238. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of diabetes? *Diabetes Care*. 2009; 32:2133-5. PMID: 19875608; PMC
239. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32:1327-34.
240. Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and ACCORD Research Groups. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. *Clin Trials* 2009; 6:416-29. PMID: 19737845; PMC
241. Ambrosius WT, Danis RP, Goff Jr. DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY for the ACCORD Study Investigators. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: The ACCORD Eye Study. *Archives of Ophthalmology*, in press, expected publication January 2010.
242. Fabiato K, Buse J, Duclos M, Largay J, Izlar C, O'Connell T, Stallings J, Dungan K. Clinical experience with continuous glucose monitoring in adults. *Diabetes Technol Ther*. 2009;11 Suppl 1:S93-S103. PMID: 19469683.
243. Dungan K, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). *Diabetes Metab Res Rev*. 2009; 25:558-65.
244. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 2009 Aug 5. Epub.
245. Buse J and Hirst K. The HEALTHY study: introduction. *International Journal of Obesity*. 2009 33 (suppl 4):1-2
246. The HEALTHY Study Group. HEALTHY study rationale, design and methods: moderating risk of type 2 diabetes in multi-ethnic middle school students. *International Journal of Obesity*. 2009 33 (suppl 4):4-20
247. Drews KL, Harrell JS, Thompson D, Mazzuto SL, Ford EG, Carter M, Ford DA, Yin Z, Jessup AN, Roulet J-B, for the HEALTHY Study Group. Recruitment and retention strategies and methods in the HEALTHY study. *International Journal of Obesity*. 2009 33 (suppl 4):21-28.
248. Gillis B, Mobley C, Stadler DD, Hartstein J, Virus A, Volpe SL, El ghormli L, Staten MA, Bridgman J, McCormick S, for the HEALTHY Study Group. Rationale, design and methods of the HEALTHY study nutrition intervention component. *International Journal of Obesity*. 2009 33 (suppl 4):29-36
249. McMurray RG, Bassin S, Jago R, Bruecker S, Moe EL, Murray T, Mazzuto SL, Volpe SL, for the HEALTHY Study Group. Rationale, design and methods of the HEALTHY study physical education intervention component. *International Journal of Obesity*. 2009 33 (suppl 4):37-43
250. Venditti EM, Elliot DL, Faith MS, Firrell LS, Giles CM, Goldberg L, Marcus MD, Schneider M, Solomon S, Thompson D, Yin Z, for the HEALTHY Study Group. Rationale, design and methods of the HEALTHY study behavior intervention component. *International Journal of Obesity*. 2009 33 (suppl 4):44-51
251. DeBar LL, Schneider M, Ford EG, Hernandez AE, Showell B, Drews KL, Moe EL, Gillis B, Jessup AN, Stadler DD, White M, for the HEALTHY Study Group. Social

- marketing-based communications to integrate and support the HEALTHY study intervention. *International Journal of Obesity*. 2009 33 (suppl 4):52-59
252. Schneider M, Hall WJ, Hernandez AE, Hindes K, Montez G, Pham T, Rosen L, Sleigh A, Thompson D, Volpe SL, Zeveloff A, Steckler A, for the HEALTHY Study Group. Rationale, design and methods for process evaluation in the HEALTHY study. *International Journal of Obesity*. 2009 33 (suppl 4):60-67
253. Jago R, McMurray RG, Bassin S, Pyle L, Bruecker S, Jakicic JM, Moe E, Murray T, Volpe S. Modifying middle school physical education: piloting strategies to increase physical activity. *Pediatric Exercise Science*. 2009, 21, 171-185.
254. HEALTHY Study Group, Kaufman FR, Hirst K, Linder B, Baranowski T, Cooper DM, Foster GD, Goldberg L, Harrell JS, Marcus MD, Treviño RP. Risk factors for type 2 diabetes in a sixth- grade multiracial cohort: the HEALTHY study. *Diabetes Care*. 2009; 32:953-5.
255. Zinman B, Gerich J, Buse J, Lewin A, Schwartz SL, Raskin P, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). *Diabetes Care* 2009; 32: 1224–1230.
256. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*. 2009; 374(9683):39-47.
257. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA*. 2009; 301:1547-55.
258. Kernan WN, Viscoli CM, Demarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI; IRIS Trial Investigators. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONS). *Neurology*. 2009; 72(15):1345-51.
259. Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrback JL, Scism-Bacon JL, Martin SA. DURABILITY of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. *Diabetes Care*. 2009; 32:1007-13.
260. Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrback JL, Jiang H, Martin S. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2009; 94:1689-94.
261. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *Am Heart J*. 2008 Oct;156(4):623-32.
262. Schneider A, Neas L, Herbst MC, Case M, Williams RW, Cascio W, Hinderliter A, Holguin F, Buse JB, Dungan K, Styner M, Peters A, Devlin RB. Endothelial dysfunction:

- associations with exposure to ambient fine particles in diabetic individuals. *Environ Health Perspect.* 2008; 116:1666-74.
263. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. *Lancet.* 2008; 372:1240-50.
264. Studies to Treat or Prevent Pediatric Type 2 Diabetes Prevention Study Group. Prevalence of the metabolic syndrome among a racially/ethnically diverse group of U.S. eighth-grade adolescents and associations with fasting insulin and homeostasis model assessment of insulin resistance levels. *Diabetes Care.* 2008; 31:2020-5.
265. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008; 358:2545-59.
266. Huizinga MM, Elasy TA, Wallston KA, Cavanaugh K, Davis D, Gregory RP, Fuchs LS, Malone R, Cherrington A, Dewalt DA, Buse J, Pignone M, Rothman RL. Development and validation of the Diabetes Numeracy Test (DNT). *BMC Health Serv Res.* 2008; 8:96.
267. Hartstein J, Cullen KW, Reynolds KD, Harrell J, Resnicow K, Kennel P for the STOPP-T2D Prevention Study Group. Impact of portion-size control for school a la carte items: changes in kilocalories and macronutrients purchased by middle school students. *J Am Diet Assoc.* 2008; 108:140-4.
268. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). *Am Heart J.* 2008; 155:26-32
269. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S 3rd, Domanski M, McKinlay S, Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. *Am Heart J.* 2008; 155:215-23.
270. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Curr Med Res Opin.* 2008; 24:275-86.
271. Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. *Diabetes Care.* 2007; 30:2892-8.
272. Dungan KM, Guster T, DeWalt DA, Buse JB. A comparison of lipid and lipoprotein measurements in the fasting and nonfasting states in patients with type 2 diabetes. *Current Medical Research and Opinion* 2007; 23:2689-2695.
273. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH for the GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 2007; 30:2458-64.
274. Byington RP, Genuth S, Friedewald WT, Simons-Morton DG. Introduction (to the ACCORD Supplement). *Am J Cardiol* 2007;99[suppl]:1i-3i.

275. Goff DC, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG for the ACCORD Study Group. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: Current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99[suppl]:4i-20i.
276. ACCORD Study Group (Writing Committee: Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC, Grimm RH, Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD). Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and methods. *Am J Cardiol* 2007;99[suppl]:21i-33i.
277. Gerstein, HC, Riddle MC, Kendall DM, Cohen RM, Golland R, Feinglos MN, Kirk JK, Hamilton BP, Ismail-Beigi F, Feeney P, for the ACCORD Study Group. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99[suppl]:34i-43i.
278. Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, Sadler LS, Alderman MH, Peterson K, Bertoni A, Basile JN, for the ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99[suppl]:44i-55i.
279. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, O'Connor PJ, Leiter LA, Weiss D, Lipkin E, Fleg JL, for the ACCORD Study Group. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99[suppl]:56i-67i.
280. Kingry C, Bastien A, Booth G, Geraci TS, Kirpach BR, Lovato LC, Margolis KL, Rosenberg Y, Sperl-Hillen JM, Vargo L, Williamson JD, Probstfield JL, for the ACCORD Study Group. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Am J Cardiol* 2007;99[suppl]:68i-79i.
281. Bonds DE, Kurashige EM, Bergenstal R, Brillon D, Domanski M, Felicetta JL, Fonseca VA, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG, for the ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Am J Cardiol* 2007;99[suppl]:80i-89i.
282. Sullivan MD, Anderson RT, Aron D, Atkinson HH, Bastien A, Chen GJ, Feeney P, Gafni A, Hwang W, Katz LA, Narayan KMV, Nwachuku C, O'Connor PJ, Zhang P, for the ACCORD Study Group. Health-related quality of life and cost-effectiveness components of the Action for Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. *Am J Cardiol* 2007;99[suppl]:90i-102i.
283. Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M, for the ACCORD Study Group. Rationale, design and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-Eye). *Am J Cardiol* 2007;99[suppl]:103i-111i.
284. Williamson JD, Miller ME, Bryan N, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ, for the ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design and methods. *Am J Cardiol* 2007;99[suppl]:112i-122i.
285. Cullen KW, Hartstein J, Reynolds KD, Vu M, Resnicow K, Greene N, White MA, Studies to Treat or Prevent Pediatric Type 2 Diabetes Prevention Study Group. Improving the school food environment: results from a pilot study in middle schools. *J Am Diet Assoc*. 107:484-9, 2007.

286. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. *Clinical Therapeutics* 29:139-53, 2007.
287. Knopp RH, d'Emden M, Smilde JG, Pocock SJ and on behalf of the ASPEN Study Group. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). *Diabetes Care* 29: 1478-1485, 2006.
288. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. *Diabetes Care* 29:1214-9, 2006.
289. Jago R, Harrell JS, McMurray RG, Edelstein S, El Ghormli L, Bassin S. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. *Pediatrics* 117:2065-73, 2006.
290. The STOPP-T2D Prevention Study Group. Presence of diabetes risk factors in a large U.S. eighth grade cohort. *Diabetes Care*. 29:212-7, 2006.
291. Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. *Clin Ther*. 27:1181-95, 2005.
292. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. *Diabetes Care* 28:1547-54, 2005.
293. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Simultaneously published *Diabetes Care* 28:2289-304, 2005 and *Diabetologia* 48:1684-99, 2005.
294. Grant RW, Buse JB, Meigs JB; University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. *Diabetes Care* 28:337-442, 2005.
295. Malhotra A, Coon H, Feitosa MF, Li WD, North KE, Price RA, Bouchard C, Hunt SC, Wolford JK, The American Diabetes Association GENNID Study Group. Meta-analysis of genome-wide linkage studies for quantitative lipid traits in African Americans. *Hum Mol Genet* 14:3955-62, 2005.
296. Malhotra A, Wolford JK, American Diabetes Association GENNID Study Group. Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study. *Diabetes* 54:3007-14, 2005.
297. Cavazzoni P, Mukhopadhyay N, Carlson C, Breier A, Buse J. Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications. *Br J Psychiatry Suppl*. 47:S94-101, 2004. Erratum in: *Br J Psychiatry* 186:449, 2005.

298. Buse J, Tan MH, Prince MJ, Erickson PP. The effects of oral antihyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 6:133-56, 2004.
299. ACCORD Study Group, Bastien A. The ACCORD trial: A multidisciplinary approach to control cardiovascular risk in Type 2 diabetes mellitus. *Practical Diabet* 23:1-7, 2004.
300. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. *Current Medical Research and Opinion* 20:215-223, 2004.
301. Barrett E, Blonde L, Clement S, Davis J, Devlin J, Kane J, Klein S, Torrey W, Allison D, Bergman R, Buse J, Cavazzoni P, Fiedorek F, Ganguli R, Greenspan A, Kendall D, Leonge R, Loebel A, Lustman P, Meltzer H, Newcomer J, Racoosin J, Roth B, Sernyak M, Thakore J, Wirshing D, Wirshing W for the American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Obesity Research* 12:362-368, 2004.
302. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 27:2628-35, 2004.
303. Wackers FJT, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE for the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Investigators. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects: The DIAD study. *Diabetes Care* 27: 1954-61, 2004.
304. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth J-P for the ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *American Journal of Nephrology* 24:32-40, 2004.
305. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J Clin Endocrinol Metab.* 88:3082-9, 2003.
306. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. *Journal of Clinical Epidemiology* 56:164-70, 2003.
307. Duggirala R, Almasy L, Blangero J, Jenkinson CP, Arya R, DeFronzo RA, Stern MP, O'Connell P, American Diabetes Association GENNID Study Group. Further evidence for a type 2 diabetes susceptibility locus on chromosome 11q. *Genet Epidemiol* 24:240-2, 2003.
308. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. *Diabetes* 51:2170-8, 2002.
309. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, Weber JL, Vaske D, Briley D, Briley L, Kopf J, McMillen P, Nguyen Q, Reisman M, Lai EH, Joslyn G, Shepherd NS, Bell C, Wagner MJ, Burns DK, American Diabetes Association GENNID Study Group. Genetics of NIDDM. Genomewide search for type 2 diabetes susceptibility genes in four

- American populations. *Am J Hum Genet* 66:1871-81, 2000. Erratum in: *Am J Hum Genet* 70:284, 2002.
310. Merz CN, Buse JB, Tuncer D, Twillman GB: Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. *Journal of the American College of Cardiology* 40:1877-81, 2002.
 311. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, and the Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. *Archives of Internal Medicine* 162:1568-76, 2002.
 312. Buse J, Hart K, Minasi L on behalf of the PROTECT Study Group. The PROTECT study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. *Clinical Therapeutics* 20(2):257-69, 1998.
 313. Buse J, Gumbiner B, Mathias NP, Nelson DM, Whitcomb RW for the Troglitazone Study Group. Troglitazone use in insulin-treated type 2 diabetic patients. *Diabetes Care* 21(9):1455-61, 1998.
 314. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, The Troglitazone Study Group, Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. *Diabetes* 46:433-9, 1997.
 315. Raffel LJ, Robbins DC, Norris JM, Boerwinkle E, DeFronzo RA, Elbein SC, Fujimoto W, Hanis CL, Kahn SE, Permutt MA, Chiu KC, Cruz J, Ehrmann DA, Robertson RP, Rotter JI, Buse J. The GENNID study. A resource for mapping the genes that cause NIDDM. *Diabetes Care* 19:864-72, 1996.
 316. Fleming GF, Vokes EE, Buse JB, Mick R, Dushay J, Levitan D, Dolan ME. Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. *Cancer Chemother Pharmacol* 37:569-73, 1996.
 317. Burant CF, Flink S, DePaoli AM, Chen J, Lee WS, Hediger MA, Buse JB, Chang EB. Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes. *J Clin Invest* 93:578-85, 1994.
 318. Olson AL, Liu ML, Moye-Rowley WS, Buse JB, Bell GI, Pessin JE. Hormonal/metabolic regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. *J Biol Chem* 268:9839-46, 1993.
 319. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF. Inhibition of glucose-stimulated insulin release from bTC3 cells and rodent islets by an analog of FK-506. *Transplantation* 55:186-92, 1993.
 320. Buse JB, Yasuda K, Lay TP, Seo TS, Olson AL, Pessin JE, Karam JH, Seino S, Bell GI. Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. *Diabetes* 41:1436-45, 1992.
 321. Liu ML, Olson AL, Moye-Rowley WS, Buse JB, Bell GI, Pessin JE. Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. *J Biol Chem* 267:11673-6, 1992.
 322. Davidson NO, Hausman AM, Ifkovits C, Buse JB, Gould GW, Burant CF, Bell GI. Human intestinal glucose transporter expression and localization of GLUT5. *Am J Physiol (Cell Physiol)* 31:C795-800, 1992.
 323. Choi WH, O'Rahilly S, Buse J, Rees A, Morgan R, Flier JS, Moller DE. Molecular scanning of the insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. *Diabetes* 40:1712-8, 1991.

324. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus. *J Clin Invest* 88:1323-30, 1991.
325. Muraoka A, Sakura H, Kim K, Kishimoto M, Akanuma Y, Buse JB, Yasuda K, Seino S, Bell GI, Yazaki Y, Kasuga M, Kadowaki T. Polymorphism in exon 4a of the human GLUT4/muscle-fat facilitative glucose transporter gene detected by SSCP. *Nucleic Acids Research* 19:4313, 1991.
326. Chang EB, Bookstein C, Vaandrager A, DeJonge HR, Buse J, Musch MW. Cystic fibrosis transmembrane regulator mRNA expression relative to ion-nutrient transport in spontaneously differentiating human intestinal CaCo-2 epithelial cells. *J Laboratory and Clinical Med* 118:377-81, 1991.
327. Fukumoto H, Kayano T, Buse JB, Edwards Y, Pilch PF, Bell GI, Seino S. Cloning and characterization of the major insulin-responsive glucose transporter expressed in human skeletal muscle and other insulin-responsive tissues. *J Biol Chem* 246:7776-9, 1989.
328. Bhatia E, Buse JB, Jackson RA. T-cell antigen receptor alpha chain polymorphism in insulin-dependent diabetes. *J Autoimmunity* 1:389-97, 1988.
329. Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, Minami M, Makino S, Moriwaki K, Kuzuya H, Imura H, Strauss WM, Seidman JG, Eisenbarth GS. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. *Science* 231:733-5, 1986.
330. Buse JB, Rifai-Haddad R, Lees S, Taniguchi H, Chaplin D, Milford EM, Seidman JG, Eisenbarth GS, Jackson RA. Major histocompatibility complex restriction fragment length polymorphisms define three diabetogenic haplotypes in BB and BBN rats. *J Exp Med* 162:444-58, 1985.
331. Buse JB, Chaplin DD, Ben-Nun A, Klein KA, Eisenbarth GS, Seidman JG, Jackson RA. Class I, II and III major histocompatibility complex gene polymorphisms in BB rats. *Diabetologia* 22:77-9, 1984.
332. Buse JB, Ben-Nun A, Klein KA, Eisenbarth GS, Seidman JG, Jackson RA. Specific class II gene polymorphism in BB rats. *Diabetes* 33:700-3, 1984.
333. Jackson RA, Buse JB, Rifai R, Pelletier D, Milford EL, Carpenter CB, Eisenbarth GS, Williams RM. Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. *J Exp Med* 159:1629-36, 1984.
334. Jackson R, Kadison P, Buse J, Rassi N, Jegasothy B, Eisenbarth GS. Lymphocyte abnormalities in the BB rat. *Metabolism* 32 (Suppl. 1):83-6, 1983.
335. Chao J, Buse J, Shimamoto K, Margolius H.S. Kallikrein-induced uterine contraction independent of kinin formation. *Proc Natl Acad Sci USA* 78:6154-7, 1981.

Refereed Papers/Articles -- Other peer reviewed papers:

1. Mendez, M.A., Drobná, Z., Fry, R., Buse, J.B., Stýblo, M., González-Horta, C., Sánchez-Ramirez, B., Ballinas, M.L., Ishida-Gutierrez, M.C., Gutiérrez-Torres, Hernández-Cerón, D.S., Viniegra-Morales, D., Baeza Terrazas, F., Del Razo, L.M., García-Vargas, G., Loomis, D. (2014) Exposure to Arsenic and Cardiometabolic Risk in Chihuahua, Mexico. In: *One Century of the Discovery of Arsenicosis in Latin America (1914-2014), As 2014, Proceedings of the 5th International Congress on Arsenic in the Environment*, 11-16 May 2014, Buenos Aires, Argentina. Marta I. Litter, Hugo B. Nicolli, Martin Meichtry, Natalia Quici, Jochen Bundschuh, Prosun Bhattacharya, Ravi Naidu, (eds), pp. 526-530. CRC Press 2014, Taylor & Francis Group, London, UK.

2. Buse JB. Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. *Nat Rev Endocrinol*. 2011; 7(2):67-8. PMID: 21263434.
3. Al-Arouj M, Assaad-Khalil S, Buse J, Fahdil I, Fahmy M, Hafez S, Hassanein M, Ibrahim MA, Kendall D, Kishawi S, Al-Madani A, Nakhi AB, Tayeb K, Thomas A. Recommendations for management of diabetes during Ramadan: update 2010. *Diabetes Care*. 2010; 33(8):1895-902. PMID: 20668157; PMC2909082.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B for the American Diabetes Association and the European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2009; 32:193-203. (Simultaneously published as *Diabetologia*. 2009; 52:17-30.)
5. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. *Diabetes Care*. 2009; 32:187-92. (Simultaneously published as *Circulation* 2009; 119:351-7 and *J Am Coll Cardiol*. 2009; 53:298-304.)
6. Hicks J, Muller M, Panteghini M, John G, Deeb L, Buse J, Nathan DM, Kahn R, Ferrannini E, Heine R, Silink M, Mbanya JC for the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Simultaneously published: *Diabetes Care* 30:2399-2400, 2007, *Clinical Chemistry* 53:1562-1564, 2007
7. Dungan K, Chapman J, Braithwaite SS, Buse J. Glucose measurement: confounding issues in setting targets for inpatient management. *Diabetes Care* 30: 403-409, 2007.
8. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes: a joint statement and recommendations from the American Diabetes Association and the American Heart Association. *Diabetes Care* 30:167-172, 2007 and *Circulation* 115:114-26, 2007.
9. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Simultaneously published: *Diabetes Care* 29:1963-1972, 2006 and *Diabetologia* 49:1711-21, 2006.
10. Buse JB, Rosenstock J. Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon. *Cardiology Clinics* 23:211-220, 2005.
11. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, Ismail-Beigi F, El-Kebbi I, Khatib O, Kishawi S, Al-Madani A, Mishal AA, Al-Maskari M, Nakhi AB, Al-Rubeanm K. Recommendations for management of diabetes during Ramadan. *Diabetes Care* 28:2305-11, 2005.
12. Hirsch IB, Bergenstal RM, Parkin CG, Wright, Jr., E, Buse JB. A real-world approach to insulin therapy in primary care practice. *Clinical Diabetes* 23:78-86, 2005.
13. Dungan K and Buse JB. Glucagon-like peptide 1-based therapies for type 2 diabetes: A focus on exenatide. *Clinical Diabetes* 23:56-62, 2005.

14. Buse JB, Rosenstock J. Prevention of cardiovascular outcomes in type 2 diabetes mellitus: trials on the horizon. *Endocrinol Metab Clin North Am.* 34:221-35, 2005.
15. ACCORD Study Group. The ACCORD Trial: A Multidisciplinary Approach to Control Cardiovascular Risk in Type 2 Diabetes Mellitus. *Practical Diabetology* 23 (4): 6-11, 2004.
16. Buse J. Statin treatment in diabetes mellitus. *Clinical Diabetes* 21:168-172, 2003.
17. Buse J. Evolution in the American Diabetes Association Standards of Care *Clinical Diabetes* 21:24-26, 2003.
18. Genuth S, Alberti KG, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160-7, 2003.
19. Buse JB. Should postprandial glucose be routinely measured and treated to a particular target? No! *Diabetes Care* 26:1615-8, 2003.
20. Buse JB. Lipid changes associated with diabetes therapy. *Practical Diabetology* 22(1):24-9, 2003.
21. Buse JB. Patient Information: Protect your heart, protect your life. *Clinical Diabetes*, 21: 173, 2003.
22. Buse JB. Practical Pointers: Statin treatment in diabetes mellitus. *Clinical Diabetes*, 21: 168-72, 2003.
23. Kendall DM, Sobel BE, Coulston AM, Peters Harmel AL, McLean BK, Peragallo-Dittko V, Buse JB, Fonseca VA, Hill JO, Nesto RW, Sunyer FX; Partners Against Insulin Resistance Advisory Panel. The insulin resistance syndrome and coronary artery disease. *Coronary Artery Disease* 14:335-48, 2003.
24. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB. Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. *Diabetes Technology and Therapeutics* 5:355-63, 2003.
25. Sherwin RS, Anderson RM, Buse JB, Chin MH, Eddy D, Fradkin J, Ganiats TG, Ginsberg H, Kahn R, Nwankwo R, Rewers M, Schlessinger L, Stern M, Vinicor F, Zinman B. The prevention or delay of type 2 diabetes. *Diabetes Care* 25:742-749, 2002.
26. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. *Clinical Diabetes* 20:137-144, 2002.
27. Buse JB. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. *Journal of Clinical Psychiatry* 63(supplement 4): 37-41, 2002.
28. Buse JB. Diabetes tactics: Aggressive treatment of type 2 diabetes. *Current Practice (The official publication of the Council for the Advancement of Diabetes Research and Education)* 1(2):4-6, 2002.
29. Fasy EA and Buse JB. Treatment of postprandial hyperglycemia in type 2 diabetes. *Postgraduate Medicine* 110 (6 suppl.):14-9, 2001.
30. Buse JB and Einhorn D. Panel discussion on achieving glycemic control. *Postgraduate Medicine* 110 (6 suppl): 20-5, 2001.
31. Buse JB. Insulin analogues. *Current Opinion in Endocrinology & Diabetes* 8:95-100, 2001.
32. American Diabetes Association. Consensus statement: postprandial blood glucose. *Diabetes Care* 24:775-778, 2001.
33. Buse JB. Progressive use of medical therapies in type 2 diabetes. *Diabetes Spectrum* 13(4): 211-220, 2000.

34. Buse JB. Combining insulin and oral agents. *American Journal of Medicine* 108 (Supplement 6a): 23-32, 2000.
35. Buse, JB. Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective. *American Journal of Managed Care* 6(suppl 13):s710-7, 2000.
36. Buse, JB. Pioglitazone in the treatment of type 2 diabetes mellitus: U.S. clinical experience. *Experimental and Clinical Endocrinology & Diabetes* (suppl 2) 108: 250-255, 2000.
37. Buse, JB. The use of insulin alone and in combination with oral agents in type 2 diabetes. *Primary Care Clinics in Office Practice* 26: 931-50, 1999.
38. Cavanagh PR, Buse JB, Frykberg, Gibbons GW, Lipsky BA, Pogach L, Reiber GE, Sheehan P, Apelqvist J, Armstrong DG, Boulton AJM, Caputo GM, Cianci P, Cohen IK, Falanga V, Foto J, Habershaw GM, Harding KG, Harkless LB, Krasner D, LoGerfo FW, Margolis D, Mayfield JA, Miller SD, Newman L, Olerud J, Ovington LG, Phillips T, Robson MC, Steed DL, Stromberg K, Ulbrecht J, Veves A. Consensus development conference on diabetic foot wound care. Simultaneously published *Diabetes Care* 22:1354-60, 1999 and *Journal of the American Podiatric Medical Association* 89:475-483, 1999.
39. Buse JB. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy. *Diabetes Care* 22(suppl. 3): c65-70, 1999.
40. Buse, JB. Management of glycemia in type 2 diabetes. *Clinical Cornerstone*. 1(3):39-57, 1998.
41. Buse JB and Hroschowski M. The case for a role of postprandial glucose monitoring in diabetes management. *Journal of Family Practice* 47(suppl.):s29-s36, 1998.
42. Sobel R, Meyer G, Buse JB. Brittle diabetes lessons for intensive insulin management. *Practical Diabetology* 13:12-22, 1994.
43. Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin D, Fukumoto H, Seino S. Molecular biology of mammalian glucose transporters. *Diabetes Care* 13:198-208, 1990.
44. Buse JB and Eisenbarth GS. Autoimmune endocrine disease. *Vitamins and Hormones* 42:253-314, 1985.
45. Buse JB and Eisenbarth GS. Monoclonal antibodies in endocrine immunodiagnosis. *Clinical Chemistry News* 9:19-21, 1982.
46. Buse JB, Rowley RH, Eisenbarth GS. Disordered cellular immunity in type I diabetes of man and the BB rat. *Survey of Immunological Research* 1:339-51, 1982.

Refereed Papers/Articles -- Editorials or Letters:

1. Neumiller JJ, Kalyani RR, Herman WH, Grant RW, Wysham CH, Inzucchi SE, Hirsch IB, Fonseca VA, Buse JB, Barrett EJ. Evidence supports prediabetes treatment. *Science*. 2019 Apr 26;364(6438):341-342. doi: 10.1126/science.aax3548. PubMed PMID: 31023917.
2. Mayer-Davis EJ, Laffel LM, Buse JB. Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet: A Word of Caution. *Pediatrics*. 2018 Aug;142(2). pii: e20181536B. doi: 10.1542/peds.2018-1536B. PubMed PMID: 30065007.
3. Kahkoska AR, Buse JB. Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention. *Diabetes Care*. 2018 Aug;41(8):1557-1559. doi: 10.2337/dci18-0020. PubMed PMID: 30030257; PubMed Central PMCID: PMC6054498.
4. Buse JB, D'Alessio DA, Riddle MC. Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes? *Diabetes Care*. 2018 Aug;41(8):1560-1562. doi: 10.2337/dci18-0025. Epub 2018 Jun 25. PubMed PMID: 29941499; PubMed Central PMCID: PMC6054497.
5. Young LA, Buse JB, Donahue KE. Concerns About Conclusions of Self-monitoring of Blood Glucose-Reply. *JAMA Intern Med*. 2017 Dec 1;177(12):1874-1875. doi:10.1001/jamainternmed.2017.6152. PubMed PMID: 29204640.

6. Mann JFE, Ørsted DD, Buse JB. Liraglutide and Renal Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Nov 30;377(22):2197-2198. doi:10.1056/NEJMc1713042. PubMed PMID: 29171823.
7. Marso SP, Buse JB. Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Nov 16;377(20):1995-1996. doi: 10.1056/NEJMc1712575. PubMed PMID: 29141162.
8. Young LA, Buse JB. The War Is Not Yet Won. *Diabetes Care*. 2017 Sep;40(9):1152-1153. doi: 10.2337/dci17-0008. PubMed PMID: 28830956.
9. Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE. Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. *Diabetes Care* 2016;39:1186-1201. *Diabetes Care*. 2017 Feb;40(2):e23-e24. doi: 10.2337/dci16-0036. PubMed PMID: 28108540.
10. Buse JB; the LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016 Nov 3;375(18):1798-9. doi: 10.1056/NEJMc1611289. PubMed PMID: 27806225.
11. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. Response to Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. *Diabetes Care* 2015; 38:1067-1074. PMID:26404938.
12. Pihlstrom BL, Buse JB. Diabetes and periodontal therapy. *J Am Dent Assoc*. 2014; 145(12):1208-10. PMID:25429029.
13. Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *Lancet*. 2014; 384(9961):2180-1. PMID: 25220193.
14. Buse JB. Type 2 diabetes mellitus in 2010: individualizing treatment targets in diabetes care. *Nat Rev Endocrinol*. 2011; 7(2):67-8. PMID: 21263434.
15. Kirk D, Buse JB. Clinical care guidelines: too much of a good thing? *Diabetes Care*. 2010; 33(12):2716-8. PMID: 21115776; PMC2992219.
16. Buse JB. Screening for diabetes and prediabetes with proposed A1C-based diagnostic criteria: comment on Olson et al. *Diabetes Care*. 2010; 33(12):e174; author reply e175. PMID: 21115761.
17. Buse JB. Can we become victims of our own success? *Diabetes Care*. 2009; 32(11):2140-1. PMID: 19875611; PMC2768205.
18. Buse JB and Falahati. Adverse events in diabetes drug trial reply. *Lancet* 374(9696): 1144-5, 2009.
19. Shen L, Kendall DM, Buse JB, Burns C, Taylor KL. Exenatide for type 2 diabetes. Reply. *Lancet* 373(9658):122-123, 2009.
20. Buse JB. A dead heat: target normal glucose levels in the intensive care unit-but with caution. *Diabetologia*. 51(6):909-10, 2008.
21. Buse JB. Are prescribing patterns of antidiabetic medications influenced by fears of litigation? *Nat Clin Pract Endocrinol Metab*. 2008; 4:440-1.
22. Carek PJ, Buse JB; Association of Family Medicine Residency Directors. Frontline: diabetes--supplementing education and quality improvement in family medicine residency training. *Ann Fam Med*. 2008;6:88-9.
23. Buse JB, Lundberg GD. Can the American Diabetes Association have an impact on preventing and treating the diabetes epidemic in 2007-2008? An interview with the incoming president. *MedGenMed*. 2007;9:9.

24. Buse J, Pignone M. Response to Dr. Nicolucci and co-workers. *Diabetes Care* 30:E---, 2007. DOI: 10.2337/dc07-0463.
25. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes - Response to Citrome et al., Giugliano and Esposito, Cheta, and Psaty et al. *Diabetes Care* 29:177-178, 2006.
26. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome. *Lancet* 366:1921-2, 2005.
27. Buse JB. Glitazones and heart failure: critical appraisal for the clinician. *Circulation*. 108(8):e57, 2003.
28. Buse J. Evolution in the ADA Standards of Care. *Clinical Diabetes* 21: 24-6, 2003.
29. Buse JB. Should postprandial glucose be routinely measured and treated to a particular target? Connecting the two sides of the debate. *Diabetes Care*. 26(9):2700-1, 2003.
30. Buse J and Raftery L. What we think and what we know. *Diabetes Care* 25:1876-8, 2002.
31. Buse JB. Diabetic genetics: a complex picture. *Consultant* 42:452, 2002.
32. Buse JB. High insulin levels: target for treatment? *Consultant* 41: 502,5, 2001.
33. Buse J. Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. *Diabetes Care*. 23:576-8, 2000.

Manuscripts in press/submitted

1. Matt Petersen, John Buse, Eric Boerwinkle, and the American Diabetes Association GENNID Study Group. GENNID: A shareable repository of genetic material for the study of type 2 diabetes. 40 pages. Resubmitted. 2006

Refereed other products of scholarship:

1. Dungan K and Buse J. Amylin and GLP-1-based therapies for the treatment of diabetes. In: UpToDate, (Rose, BD, editor). UpToDate, Wellesley, MA, 2005-2007.
2. Perkins DO, Keefe RSE, Citrome L, Buse, JB Liffick, LF. CME Circle: Enhancing Outcomes by Addressing Critical Challenges in the Treatment of Schizophrenia. Medscape Psychiatry and Mental Health. Posted: 9/26/03. Available at: <http://www.medscape.com/viewprogram/2632>.
3. Zinman B, Malik RA, Gardner TW, Taylor R, Buse JB. CME Circle: Pathways Leading to Diabetic Microvascular Complications and the Latest Clinical Therapies. Medscape Diabetes and Endocrinology. Posted: 9/22/03. Available at: <http://www.medscape.com/viewprogram/2636>.
4. Buse JB. Ask the Expert: Waiting for a Change in A1C. Medscape Diabetes and Endocrinology. Posted: 9/9/03. Available at: <http://www.medscape.com/viewarticle/460876>.
5. Buse JB. Clinical Update: Diabetes Management in the 21st Century: Multiple Therapeutic Options for Achieving Glycemic Control. Medscape Diabetes and Endocrinology. Posted: 12/13/2000. Available at <http://www.medscape.com/viewprogram/595>.
6. Buse. JB. Ask the Expert: A Case of Malingering? Medscape Diabetes and Endocrinology. Posted:3/14/03. Available at: <http://www.medscape.com/viewprogram/595>.
7. Buse JB. Ask the Expert: The Lowest Glucose of the Day. Medscape Diabetes and Endocrinology. Posted: 3/11/03. Available at: <http://www.medscape.com/viewarticle/450197>.
8. Buse JB. Ask the Expert: Alpha-glucosidase Inhibitors for Type 1 Diabetes. Medscape Diabetes and Endocrinology. Posted: 11/13/01. Available at: <http://www.medscape.com/viewarticle/412376>.

9. Buse, JB. Ask the Expert: Rotating Injection Sites. Posted: 10/04/01. Available at: <http://www.medscape.com/viewarticle/412395>.
10. Buse JB. Ask the Expert: Agents Interfering with Home Testing of Blood Glucose. Medscape Diabetes and Endocrinology. Posted: 9/25/01. Available at: <http://www.medscape.com/viewarticle/412368>.
11. Buse JB. Ask the Expert: The Severely Insulin-Resistant Patient with Anti-Insulin Antibodies. Medscape Diabetes and Endocrinology. Available at: <http://www.medscape.com/viewarticle/412371>.
12. Buse JB. Ask the Expert: Risk of Hepatotoxicity with New Thiazolidinediones. Medscape Diabetes and Endocrinology. Available at: <http://www.medscape.com/viewarticle/412413>.

Other:

1. Buse JB, Henry RR. A practical approach to the management of type 2 diabetes in the context of cardiovascular risk. *Pri-Med in Practice*. Primed, Boston, MA, 2006. 2 pages
2. Hirsch IB, Blonde L, Buse J, Close K, Edelman SV, Peters A, Valentine V, Wysham C, Garg S. Consensus Development Conference on Pramlintide in the Management of Type 1 and Type 2 Diabetes. The Diabetes Education Group, Lakeville, CT, 2006. 16 pages.
3. Management of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State in Adults. (JB Buse, M Menke, TS Sisca, editorial review board). Scherer Clinical Communication, 2005. 24 pages.
4. Anonymous. Diabetic Ketoacidosis in the Adult Patient. (John B. Buse, Thomas S. Sisca, Marsha Menke, editorial review board). HealthAnswers, Inc. 2002
5. Buse JB. Recent findings: five epidemiological studies who comparable rates of diabetes among antipsychotic agents. In: *Clinical Perspectives in Psychiatry*. Medical Education Network, New York, 2002
6. Buse JB. Metabolic Side Effects: Focus on Hyperglycemia and Diabetes. In: *JCP Visuals*. Physicians Postgraduate Press, Inc., 2002 (2 pages).
7. Buse JB. Diabetes Treatment: Focus on Postprandial Glucose. In: *Postprandial Hyperglycemia in Type Diabetes*. Postgraduate Institute for Medicine, 2002 (3 pages).
8. Anonymous. The Basics of Continuous Subcutaneous Insulin Infusion Therapy. Editorial Review Board (John B. Buse, Thomas S. Sisca, Jane Young). HealthAnswers, Inc. 2002.
9. Buse JB. New treatment strategies for type 2 diabetes: Where are we now and where are we going?. In: *Current Diabetes Care: The evolving role in the pharmacist and emerging treatment strategies*. BioScience Communications, New York, NY, 2001. (7 pages)
10. Anonymous. American Pharmaceutical Association New Product Bulletin. Lantus (insulin glargine). Advisory Board (Chair: John R. White; Members: Janelle F. Bagsall, John B. Buse, Betsy A. Carlisle). American Pharmaceutical Association, Washington, DC, 2000.
11. Bruntlett E and Buse JB. The role of medical nutrition therapy in type 2 diabetes. In: *Mediguide to Diabetes* (Whitehouse FW, ed.). Lawrence DellaCorte Publications, Inc, New York, NY. 4(5):1-6, 1998.
12. Kahn C, Buse JB, Lebovitz HE, Nadeau D. Postprandial hyperglycemia: Implications for NIDDM. Boston. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
13. Golden TD, Buse JB, Lebovitz HE. Postprandial hyperglycemia: Implications for NIDDM. Atlanta. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
14. Baron AD, Buse JB, Lebovitz HE. Postprandial hyperglycemia: Implications for NIDDM. Chicago. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
15. Davidson JA, Lebovitz HE, Buse JB, Svec F. Postprandial hyperglycemia: Implications for NIDDM. Dallas. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)

16. Edelman SV, Buse JB, Lebovitz HE. Postprandial hyperglycemia: Implications for NIDDM. San Fransisco. Pharmedica Press, Killingworth, CT. December, 1997. (12 pages)
17. Buse JB. Myths Regarding Diabetes Care and Coronary Disease. Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1999, 4 pages.
18. Buse JB. Advances in Diabetes Treatment - Implications for Lipid Management. Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1999, 4 pages.
19. Buse JB. Insulin Resistance: Role in the Clinical Management of Diabetes. Pharmedica Communications, Killingworth, CT. 1999, 24 pages.
20. Buse JB and Bruntlett EQ. Making Nutrition Work in the Management of Type 2 Diabetes: A Guide for Patients. Bayer Corporation, West Haven, CT. 1999, 13 pages.
21. Buse JB and Bruntlett EQ. Making Nutrition Work in the Management of Type 2 Diabetes: A Guide for Diabetes Care Providers. Bayer Corporation, West Haven, CT. 1999. 38 pages.
22. Buse J. Diabetic Emergencies. Acute Glycemic Control. In: *Patterns of Care: Guidelines for Diabetes Care*. Patterns of Care Task Force. The North Carolina Diabetes Advisory Council. Raleigh, NC. 1999, 11 pages.
23. Buse J and Yarborough P. Diabetes Management. Long Term Glycemic Control. In: *Patterns of Care: Guidelines for Diabetes Care*. Patterns of Care Taks Force. The North Carolina Diabetes Advisory Council. Raleigh, NC. 1999, 11 pages.
24. Berlin C and Buse J. Is there a role for cardiovascular risk factor reduction in pre-menopausal woman with diabetes? Lipid Nurse Task Force Newsletter, Milwaukee, WI. 1998, 3 pages.
25. Buse, JB. Review of Ralph DeFronzo's *Current Therapy of Diabetes Mellitus*. *Annals of Internal Medicine*. 128:331-2, 1998.
26. Buse JB, Edelman SV, Knudson PE. *Clinical Case Studies in Diabetes. Pearls and Pitfalls. A Focus on NIDDM for the Specialist*. (AD Baron, ed). Clinical Communications, Greenwich, CT. 1997 (33 pages).
27. Buse JB, Edelman SV, Knudson PE. *Clinical Case Studies in Diabetes. Pearls and Pitfalls. A Focus on NIDDM*. (AD Baron, ed). Clinical Communications, Greenwich, CT. 1997 (33 pages).
28. Buse, JB. Review of Ralph DeFronzo's *Current Therapy of Diabetes Mellitus*. Doody's Review Service (on-line). Available at <http://www.doody.com>. December 1, 1997.

Teaching Record

Lectures:

Course Co-Director, Management of Diabetes Mellitus (MEDI 608, NURS 608, PHCY 608; 2003-2013)

Course Director, Biomedical Sciences Selective on Diabetes (Spring, 1997)

Approximately 2 sessions per year in "The Endocrine System: Mechanisms of Disease", second year course, School of Medicine.

Approximately 1-2 per year to graduate students in the each of the following at UNC:

School of Public Health, Department of Nutrition

School of Nursing

School of Medicine

Approximately 4 per year to residents, faculty and fellows in the Department of Medicine

Approximately 2 per year in the other Departments within the School of Medicine

Clinical Teaching:

Two teaching clinics every month with Endocrinology Fellows

Inpatient consult service attending ~12 days per year
 Visiting trainees from the School of Medicine, Nursing, School of Public Health, School of Pharmacy, School of Social Work, AHEC Visiting Faculty Program

Continuing Education Lectures:

Sponsored by UNC-CH AHEC - Approximately two per year
 Sponsored by other NC AHEC's - Approximately two per year
 Sponsored by other medical schools - Approximately five per year
 National/International meetings – Approximately 20 per year (e.g., American Diabetes Association, European Association for the Study of Diabetes)
 Commercial CME providers – Approximately 20 per year
 To lay audiences – Approximately 5 per year

Student preceptorship:

Each summer one funded student works in the diabetes program; previous students have come from the School of Pharmacy, School of Public Health, School of Medicine and the undergraduate campus

Attending on Clinical Teaching Services:

General Internal Medicine Inpatient Service (1995-1997, 2001-2006)
 Endocrine Consult Service (1994-2002; 2008-present)
 General Medicine Consult Service (2001-2005)

Graduate Student Committees:

Alisa Hughley, PhD; School of Public Health
 Debra Muio, PhD; Department of Nutrition
 Carmen Samuel-Hodge, PhD; Department of Nutrition
 Chester Lee Costales, PhD; School of Pharmacy
 Mugdha Gokhale, PhD; School of Public Health
 Rowan Far Beck, PhD candidate, School of Medicine (Genetics and Molecular Biology)
 Anna Kahkoska, PhD candidate, School of Public Health (MD, PhD program)
 Liz Garry, PhD, School of Public Health

Internal Medicine Residents:

Coach (2018-president)

Grants

Current Support:

LEADER	Buse	01/06/11 - analysis only
Novo-Nordisk		
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results. A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events		
Role: Overall PI, Chair of the Executive Steering Committee and Site Co-I		
No number	Buse	04/04/11 - analysis only
Medtronic (investigator initiated)		

Examining the Role of CGM in Non-Insulin Treated Type 2 Diabetes, A two-site pilot study
Role: Overall study PI, Site Co-PI

1R01HL110380-01 Buse and Wagner (UNC) 09/01/12 – analysis only
NIH/NHLBI

Genome-Wide Association Study of ACCORD Lipid Trial
A study to examine the pharmacogenomics of fenofibrate treatment on lipid profile and genetic variants associated with anti-hyperglycemic response
Role: Corresponding Co-PI

1U01DK098246 Lachin (Georgetown) 09/01/12 - 08/31/20
NIH/NIDDK

The Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study
Multi-center trial of comparative effectiveness in type 2 diabetes.
Role: Executive Committee Member; Chair, Protocol Oversight Subcommittee; Site Co-Investigator

09-1 Buse 09/01/12 - analysis only
GI Dynamics, Inc.

EndoBarrier: a Novel therapy for type 2 Diabetes and Obesity (ENDO Trial)
Sham-controlled study of a gastrointestinal sleeve to improve glycemia and reduce weight in type 2 diabetes.
Role: Site PI, Co-Chair of Executive Committee

ADA (Gu [NC State]) 11/01/2015-12/31/2019
American Diabetes Association
Bio-Inspired Synthetic Pathway for Closed-Loop Delivery of Insulin and Glucagon
Dr. Buse is a co-investigator in this study aiming to develop a glucose responsive insulin formulation.

NN9924-4257 (Buse) 09/01/2016-08/30/2019
Novo Nordisk
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus
Dr. Buse is site PI for this phase III study and the Signatory Investigator for the study.

3UC4DK108612 (Damiano [Boston University]) 09/30/2016 – 09/29/2019
NIH/NIDDK
Final clinical studies for submission of pre-market approval application to the FDA for a bionic pancreas that automates type 1 diabetes management
Dr. Buse is a co-investigator and site-PI for this clinical trial of bionic pancreas technology in type 1 diabetes management.

PCORI (Buse/Rothman [Vanderbilt]/Schatz [Florida]) 01/01/2017-10/31/2018
PCORI
Diabetes and Obesity Collaborative Research Group
Dr. Buse is the Corresponding co-PI for this proposal to generate proposals for diabetes and obesity studies for PCORnet

NN9924-4280 (Buse) 02/01/2017-01/31/2019
Novo Nordisk
Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes

Mellitus treated with insulin. (Pioneer 8)

Dr. Buse is the signatory investigator and site PI for this phase III trial.

VTV TTP399-203 (Buse)

10/01/2017-06/30/2018

VTV Therapeutics

A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, And Tolerability Of TTP399 In Adult Patients With Type 1 Diabetes Mellitus

Dr. Buse is the signatory investigator and site PI for this adaptive phase II trial.

PCORI (Roumey [Vanderbilt])

11/2017 – 10/2018

Rapid response project to develop, validate and examine computable phenotypes for diabetes, its comorbidities, and medications for inclusion in PCORnet common data model.

Role: Site PI and co-investigator.

EFC- 14868 (Buse)

12/01/2017-11/30/2019

Sanofi

Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Anti-diabetes Drugs

Dr. Buse is the site PI for this phase III trial.

EFC-15294 (Buse)

02/01/2018-1/31/2020

Sanofi

A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study with a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 years or Older with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

Dr. Buse is the site PI for this phase III trial.

UL1TR002489 (Buse/Carey)

03/30/2018 – 02/28/2023

NIH NCATS

North Carolina Translational and Clinical Sciences Institute (NC TraCS)

This application provides 5 years of support for UNC-CH's CTSA award. The work proposed in this CTSA is designed to transform clinical and translational science at UNC and beyond. Dr. Buse is the corresponding co-Principal Investigator for the UNC-CH CTSA effort.

1R01DK112939 (Gu, UCLA)

06/15/2018-05/31/2023

NIH NIDDK

Towards Glucose Transporter-Mediated Glucose-Responsive Insulin Delivery with Fast Response

Dr. Buse is a co-investigator on this study to develop glucose-responsive insulin delivery system in mice, translate into large animal models and prepare for phase 1 human trials.

U54DK118612 (Philipson, University of Chicago)

09/10/2018 – 05/31/2019

Subcontract from University of Chicago

Center for the Identification of Individuals with Atypical Diabetes Mellitus

This application provides 5 year support with the first year dedicated to establishing infrastructure and policies regarding the effort to identify and characterize atypical cases of diabetes.

Site PI and member of several subcommittees

RI-CRG-1807-004 (Buse/Rothman [Vanderbilt]/Schatz [Florida]) 11/01/2018-10/31/2019
PCORI

Diabetes and Obesity Collaborative Research Group

Dr. Buse is the Corresponding co-PI for this proposal to generate proposals for diabetes and obesity studies for PCORnet

1R01DK119913-01 (McClain, Wake Forest University 01/20/2019-12/31/2023
NIH NIDDK

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

Dr. Buse is the site-PI for this two-site clinical trial of phlebotomy as a treatment for hyperglycemia.

Prior Support

Over 200

Professional Service

Society Memberships:

American Association of Clinical Endocrinologists

1998-2010 Carolinas Affiliate Board Member

American Diabetes Association

2017-present Member, Emeritus Council

2017-present Member, Heritage Council

2017-2018 Chair, Type 2 Diabetes Management Guideline Writing Group

2014-2016 Member, Award Selection Committee

2013- 2017 Member, Pathway Mentor Advisory Group

2009 Member, Board of Directors

2007-2008 President for Medicine and Science

2006-2007 President-Elect

2005-2006 Vice-President

2001-2004 National Board Member

1997-2001 Southern Region Board Member

1996 President, North Carolina Affiliate

1994 Northern Illinois Board Member

Endocrine Society

Society of General Internal Medicine

Consultant (under contracts from UNC):

Adocia

AstraZeneca

Dance Biopharm

Dexcom

Elcelyx Therapeutics

Eli Lilly and Company

Fractyl

GI Dynamics

Intarcia

Lexicon

LipoScience

Merck
Metavention
NovaTarg Therapeutics
Novo Nordisk
Orexigen
Quest
Sanofi
Shenzen HighTide
Quest
Takeda
vTv Therapeutics

Consultant: Mellitus Health
PhaseBio
Stability Health
Whole Biome

Editorial appointments:

Diabetes Research & Clinical Practice (Editorial Board, 2008-present)
Diabetes Technology & Therapeutics (Editorial Board, April 2006-present)
International Journal of Diabetes & Metabolism (International Advisory Board, December 2005-present)
Clinical Diabetes (Associate Editor, July 2002-December 2005)
Diabetes Care (Associate Editor, 1998-2001, Editorial Board 2013-2018)

Reviewer: American Journal of Medicine
American Journal of Physiology
Archives of Pathology and Laboratory Medicine
Diabetes
Diabetes Care
Diabetes, Metabolism and Obesity
Diabetic Medicine
Diabetologia
Gastroenterology
Journal of the American Medical Association
Journal of Cardiopulmonary Rehabilitation
Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Epidemiology
Journal of Clinical Investigation
Journal of Nutritional Biochemistry
Lancet
Lancet Diabetes and Endocrinology
New England Journal of Medicine

Committees:

University: Chair, Clinical Trials Advisory Committee (2018-present)
Member, Business of Health Care Steering Committee (2017-present)
Chair, Pediatrics Chair Search Committee (2017- 2018)
Chair, Scientific Review Committee (2016-present)

- Member, Provost's Committee on Clinical Trial Infrastructure (2016-17)
- Member, Office of Human Research Ethics Search Committee (2014-present)
- Chair, Scientific Review Sub-Committee of the Biomedical Institutional Review Board (2012-2016)
- Member, Biomedical Institutional Review Board (2012-2016)
- Chair, Office of Clinical Trials Advisory Committee (2012-present)
- Co-Chair, Search Committee for Director, Office of Clinical Trials (2011-2013)
- Member, Clinical Trials Task Force (2011)
- Member, various Leadership Committees, NC Translational and Clinical Science Institute (2008-present)
- Member, Steering Committee, NC Translational and Clinical Science Institute (2008-present)
- Member, Grant Review Panel, NC Translational and Clinical Science Institute (2008-2010)
- Member, Carolina Speakers (2007-present)
- School of Medicine Member, Workgroup on Clinical Research (2018-present)
- Member, MD-PhD Executive Committee (2017-present)
- Member, Center for Health Equity Research Internal Advisory Board (2017-present)
- Co-Chair, Carolina Value Clinical Research Committee (2015-2016)
- Member, Informatics Technology Governance Committee (2014-2017)
- Chair, Strategic Plan Subcommittee on Team Science (2012-2016)
- Committee Chair, Diabetes Center Director Search Committee (2010-2011)
- Interim Director, Diabetes Center (2010-present)
- Faculty Advisor, MD-PhD Team 2 (2010-present)
- Member, Investigational Drug Service Advisory Committee (2007-present)
- Member, Carolina Center for Clinical Trials Advisory Board (2006-2008)
- Founder, Diabetes Interest Group (2005-2008)
- Member, Task Force on Pharmacy and Uncompensated Care (2004)
- Member, Pharmacy and Therapeutics Committee (2001-present)
- Member, Ambulatory Care Operations Group (2001-2007)
- Chair, Thurston Arthritis Research Center Director Search Committee (2001-2003)
- Chair, Ophthalmology Chair Search Committee (1999-2000)
- Member, UNC Clinical Research Advisory Committee (1995-1997)
- State Member, Diabetes Advisory Council, Department of Environment, Health and Natural Resources (2010-present)
- Member, Patterns of Care Task Force of the North Carolina Diabetes Advisory Council, Department of Environment, Health and Natural Resources (1995-2010)

Regional	Member, Board of Directors, Carolinas Chapter of the American Association of Clinical Endocrinologists (1999-2008)
National	<p>Chair, Peer Reviewed Medical Research Program Panel, Department of Defense (2018- present)</p> <p>Member, Semaglutide Pragmatic Trial Steering Group (2018-present)</p> <p>Member, PREDICTS DSMB (clinical trial of disease management in prediabetes 2018-present)</p> <p>Member, Diabetes Self-management Education and Support Advisory Council (CDC-funded project at UNC, 2017- present)</p> <p>Co-Chair, PCORI/NIDDK/NHLBI Cardiovascular Clinical Trial Workgroup (2017-2018)</p> <p>Member. CTSA Methods and Processes Domain Task Force Lead Team. NCATS. (2017-present)</p> <p>Chair, External Advisory Committee. South Carolina Translational Research (SCTR) Institute (MUSC CTSA). (2016-present)</p> <p>American Diabetes Association representative, Diabetes Collaborative Registry Research and Publications Subcommittee (2014-present)</p> <p>Chair, SAGE (AstraZeneca) Advisory Committee (2014-2016)</p> <p>Chair, National Diabetes Education Program Adherence Task Group (2014-2016)</p> <p>Member, American Diabetes Association Pathway review/mentorship committee (2013-present)</p> <p>Chair, National Diabetes Education Program, a joint venture of NIDDK and CDC (2012-2014)</p> <p>Co-chair, ENDO (GIDynamics) Steering Committee (2012-2016)</p> <p>Chair, Protocol Oversight Committee, GRADE Trial, NIDDK (2012-present)</p> <p>Member, Steering Committee, GRADE Trial, NIDDK (2012-present)</p> <p>Member, LIGHT (Contrave CVOT) Executive Steering Committee (2012-2016)</p> <p>Member, Steering Committee, FLAT-SUGAR Trial, University of Washington (2012)</p> <p>Member, T1D Exchange Oversight Committee (2011-2015)</p> <p>Member, Steering Committee, Cystic Fibrosis Related Diabetes Study Group, NIDDK (2011-2016)</p> <p>Member, Operations Committee, National Diabetes Education Program, National Institutes of Health (2011-2012)</p> <p>Vice-Chair, ACCORDion (Action to Control Cardiovascular Risk in Diabetes Follow-up Study) Study, NIH/NHLBI (2011-2017)</p> <p>Member, AstraZeneca Healthcare Foundation Board (2010-2017)</p> <p>Member, Health Care Professional Work Group of the National Diabetes Education Program, National Institutes of Health (2009-11)</p> <p>Member, Board of Director, DiabetesSisters (2010-2014)</p> <p>Member, Clinical Guidelines Leadership Group for Cardiovascular Risk Reduction, NHLBI (2009-2012)</p> <p>Member, Diabetes Research Strategic Plan Committee, NIDDK (2008-10)</p>

Chair, TrialNet External Advisory Committee, NIDDK (2006-present)

Member, Diabetes Mellitus Interagency Coordinating Committee, NIH (2006-2008)

Member, IOOV Data Safety Monitoring Board, Eli Lilly & Co. (2006-10)

Member, BHT-3021 Protocol Data Safety and Monitoring Board, Bayhill Therapeutics (2006-2012)

Member, IRIS (Insulin Resistance Intervention After Stroke) Data Safety Monitoring Board, NINDS (2004-2016)

Member, NASH-CRN (Non-Alcoholic SteatoHepatitis Clinical Research Network) Data Safety Monitoring Board, NIDDK (2004-2011)

Chair, STOPP-T2D (Studies to Treat Or Prevent Pediatric Type 2 Diabetes) Prevention Study Publications and Presentations Committee (2004-2016)

Member, Experienced Reviewer Reserve, NIDDK (2003-present)

Member, FREEDOM (Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease) Trial Steering Committee, NHLBI (2003-2014)

Member, NAVIGATOR US Steering Committee, Novartis (2002-2011)

Chair, Diabetes Cardiovascular Disease Advisory Committee, American Diabetes Association (2001-2008)

Chair, Archimedes Project Advisory Committee, American Diabetes Association (2002-2008)

Vice-Chair, ACCORD (Action to Control Cardiovascular Risk in Diabetes) Study, NIH/NHLBI (2000-10)

Co-Director, American Diabetes Association Postgraduate Course (2003)

Member, National Board, American Diabetes Association (2001-2004)

Co-Chair, American Association of Clinical Endocrinologists 2000 Annual Meeting Program Committee (1999-2000)

Chair, Professional Practice Committee, American Diabetes Association (2002-2004)

Member, Professional Practice Committee, American Diabetes Association (1999-2004, 2009-2010)

Chair, Data Safety Monitoring Board, CONTROL (Combination Oral & Nutritional Treatment of Late-Onset Diabetes Mellitus) Trial (1999-2000)

Member, Scientific and Medical Meetings Oversight Committee, American Diabetes Association (1997-1999)

Member, Professional Education Project Team, American Diabetes Association (1996-1997)

Member, Medical Science Review Committee, Juvenile Diabetes Foundation International (1996-1998)

Member, ENABLE Steering Committee (pragmatic trial of podiatric services in dialysis centers in Canada, 2018-present)

Co-Chair, ADA/EASD Medical Management of Type 2 Diabetes writing group (2017-present)
Co-Chair, SOUL (semaglutide CVOT) Steering Committee (2017-present)
Co-chair, DEVOTE (degludec CVOT) Steering Committee (2013-2017)
Juror, Harold Hamm International prize for Biomedical Research in Diabetes, (2012-2013)
Chair, LEADER Trial (**L**iraglutide **E**ffect and **A**ction in **D**iabetes: **E**valuation of Cardiovascular Outcome **R**esults) Steering Committee (2010-2017)
Member, EXSCEL Steering Committee (Exenatide Study of Cardiovascular Event Lowering) Steering Committee (2010-2017)
Member, ALECARDIO Steering Committee, Hoffman LaRoche (2010-2014)
Member, TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) Steering Committee (2009-2016)
Member, Steering Committee, NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) Trial (2002-2012)
Member, Independent Data Monitoring Committee, ORIGIN (Outcome Reduction with Initial Glargine Intervention) Trial (2003-2012)

Other Administrative Activities:

Director, NC Translational and Clinical Sciences Institute (home of the UNC CTSA award), (2015-present)
Deputy Director, NC Translational and Clinical Sciences Institute (home of the UNC CTSA award), (2013-2015)
Executive Associate Dean for Clinical Research, UNC School of Medicine (2011-present)
Director, Clinical and Translational Research Center, UNC School of Medicine (2011-2012)
Interim Director, Diabetes Center for Excellence, UNC School of Medicine (2010-present)
PI-extender for Clinical Research, Translational and Clinical Sciences Institute (home of the UNC CTSA award), (2008-2013)
Chief, Division of Endocrinology, Department of Medicine, UNC School of Medicine (2007-present)
Chief, Division of General Medicine and Clinical Epidemiology, Department of Medicine, UNC School of Medicine (2001-2006)
Clinic Director, Highgate Specialty Centre, UNC Hospitals and Clinics (1999-2008)
Director, Endocrinology Clinics, Division of Endocrinology, Department of Medicine, UNC School of Medicine (1997-2007)
Director, Diabetes Care Center, Division of Endocrinology, Department of Medicine, UNC School of Medicine (1994-present)
Co-Chief, Division of Endocrinology, Department of Medicine, UNC School of Medicine (1997-2002)

Patents

Buse JB, Moses AC. Integrated sample acquisition and analyte measurement device. U.S. Patent 8,795,176. Issued August 5, 2014

Buse JB, Moses AC. Methods of determining analyte concentration. U.S. Patent 8,532,731. Issued September 10, 2013.

Buse JB, Dungan K, Wittlin SD, Button EA, Kato S, Tanabe T. Method of estimation of blood glucose excursions in diabetic patients using 1,5-anhydroglucitol (1,5-AG) assay. U.S. Patent 8,178,312. Issued May 15, 2012.

Buse JB, Moses AC. Methods of determining concentrations of glucose. US Patent 7,740,581. Issued June 20, 2010.

Buse JB, Moses AC. Methods of determining concentrations of glucose. US Patent 7,058,437. Issued June 6, 2006.

Buse JB, Moses AC. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator. US Patent 6,591,125. Issued July 8, 2003.